BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297-2307. [PMID: 17135584 DOI: 10.1056/nejmoa060326] [Cited by in Crossref: 1165] [Cited by in F6Publishing: 442] [Article Influence: 72.8] [Reference Citation Analysis]
Number Citing Articles
1 Lewis JR, Mohanty SR. Nonalcoholic Fatty Liver Disease: A Review and Update. Dig Dis Sci 2010;55:560-78. [DOI: 10.1007/s10620-009-1081-0] [Cited by in Crossref: 212] [Cited by in F6Publishing: 211] [Article Influence: 17.7] [Reference Citation Analysis]
2 Takaki A, Kawano S, Uchida D, Takahara M, Hiraoka S, Okada H. Paradoxical Roles of Oxidative Stress Response in the Digestive System before and after Carcinogenesis. Cancers (Basel) 2019;11:E213. [PMID: 30781816 DOI: 10.3390/cancers11020213] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
3 Bloomgarden ZT. The 6th Annual World Congress on the Insulin Resistance Syndrome. Diabetes Care 2009;32:e127-33. [PMID: 19875596 DOI: 10.2337/dc09-zb11] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
4 Kawaguchi T, Nakano D, Oriishi T, Torimura T. Effects of isomaltulose on insulin resistance and metabolites in patients with non‑alcoholic fatty liver disease: A metabolomic analysis. Mol Med Rep 2018;18:2033-42. [PMID: 29956790 DOI: 10.3892/mmr.2018.9223] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Coppola M, Glinni D, Moreno M, Cioffi F, Silvestri E, Goglia F. Thyroid hormone analogues and derivatives: Actions in fatty liver. World J Hepatol 2014; 6(3): 114-129 [PMID: 24672641 DOI: 10.4254/wjh.v6.i3.114] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
6 Ferrari SM, Fallahi P, Vita R, Antonelli A, Benvenga S. Peroxisome Proliferator-Activated Receptor- γ in Thyroid Autoimmunity. PPAR Res 2015;2015:232818. [PMID: 25722716 DOI: 10.1155/2015/232818] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
7 Cheng HS, Tan WR, Low ZS, Marvalim C, Lee JYH, Tan NS. Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. Int J Mol Sci. 2019;20. [PMID: 31614690 DOI: 10.3390/ijms20205055] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 15.3] [Reference Citation Analysis]
8 Erion DM, Park HJ, Lee HY. The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. BMB Rep. 2016;49:139-148. [PMID: 26728273 DOI: 10.5483/bmbrep.2016.49.3.268] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
9 Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017;177:633-640. [PMID: 28241279 DOI: 10.1001/jamainternmed.2016.9607] [Cited by in Crossref: 151] [Cited by in F6Publishing: 143] [Article Influence: 30.2] [Reference Citation Analysis]
10 Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease. Nat Rev Endocrinol 2017;13:572-87. [PMID: 28731034 DOI: 10.1038/nrendo.2017.80] [Cited by in Crossref: 331] [Cited by in F6Publishing: 311] [Article Influence: 66.2] [Reference Citation Analysis]
11 Kalavalapalli S, Bril F, Koelmel JP, Abdo K, Guingab J, Andrews P, Li WY, Jose D, Yost RA, Frye RF, Garrett TJ, Cusi K, Sunny NE. Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis. Am J Physiol Endocrinol Metab 2018;315:E163-73. [PMID: 29634314 DOI: 10.1152/ajpendo.00023.2018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
12 Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, Muggeo M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51:444-450. [PMID: 18058083 DOI: 10.1007/s00125-007-0897-4] [Cited by in Crossref: 198] [Cited by in F6Publishing: 174] [Article Influence: 13.2] [Reference Citation Analysis]
13 Lingvay I, Raskin P, Szczepaniak LS. Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications 2007;21:137-42. [PMID: 17493545 DOI: 10.1016/j.jdiacomp.2007.02.005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
14 Erion DM, Shulman GI. Diacylglycerol-mediated insulin resistance. Nat Med. 2010;16:400-402. [PMID: 20376053 DOI: 10.1038/nm0410-400] [Cited by in Crossref: 294] [Cited by in F6Publishing: 281] [Article Influence: 24.5] [Reference Citation Analysis]
15 Cauchy F, Belghiti J. A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma. J Hepatocell Carcinoma 2015;2:19-27. [PMID: 27508191 DOI: 10.2147/JHC.S44521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 30.5] [Reference Citation Analysis]
17 Sterling RK, Sanyal AJ. Pentoxifylline for steatohepatitis: magic bullet or smoking gun? Hepatology 2011;54:1496-9. [PMID: 22045667 DOI: 10.1002/hep.24612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
18 Lian J, Fu J. Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. Front Endocrinol (Lausanne) 2021;12:615409. [PMID: 33995271 DOI: 10.3389/fendo.2021.615409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Saponaro C, Gaggini M, Gastaldelli A. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. Curr Diab Rep. 2015;15:607. [PMID: 25894944 DOI: 10.1007/s11892-015-0607-4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 8.7] [Reference Citation Analysis]
20 Yan H, Xia M, Chang X, Xu Q, Bian H, Zeng M, Rao S, Yao X, Tu Y, Jia W. Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study. PLoS One. 2011;6:e24895. [PMID: 21949781 DOI: 10.1371/journal.pone.0024895] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 5.6] [Reference Citation Analysis]
21 Ratziu V. Management of nonalcoholic steatohepatitis: Pharmacotherapy. Clin Liver Dis (Hoboken) 2012;1:122-4. [PMID: 31186867 DOI: 10.1002/cld.74] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Alqahtani SA, Schattenberg JM. NAFLD in the Elderly. Clin Interv Aging 2021;16:1633-49. [PMID: 34548787 DOI: 10.2147/CIA.S295524] [Reference Citation Analysis]
23 Cusi K. Focus on the Type 2 Diabetes Patient with Liver Disease: Emphasis on Nonalcoholic Fatty Liver Disease (NAFLD). Endocrine Practice 2011;17:9-13. [DOI: 10.1016/s1530-891x(20)43146-5] [Reference Citation Analysis]
24 DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53:1270-1287. [PMID: 20361178 DOI: 10.1007/s00125-010-1684-1] [Cited by in Crossref: 489] [Cited by in F6Publishing: 439] [Article Influence: 40.8] [Reference Citation Analysis]
25 Morris EM, Rector RS, Thyfault JP, Ibdah JA. Mitochondria and redox signaling in steatohepatitis. Antioxid Redox Signal 2011;15:485-504. [PMID: 21128703 DOI: 10.1089/ars.2010.3795] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
26 Lacasse MC, Tang A, Dubois J, Alvarez F, Spahis S, Chagnon M, Deschênes S, Levy E. Monitoring the efficacy of omega-3 supplementation on liver steatosis and carotid intima-media thickness: a pilot study. Obes Sci Pract 2017;3:201-11. [PMID: 28702213 DOI: 10.1002/osp4.91] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
27 Abd El-Kader SM, El-Den Ashmawy EMS. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol 2015; 7(6): 846-858 [PMID: 25937862 DOI: 10.4254/wjh.v7.i6.846] [Cited by in Crossref: 166] [Cited by in F6Publishing: 148] [Article Influence: 23.7] [Reference Citation Analysis]
28 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-48. [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 8.3] [Reference Citation Analysis]
29 Xing B, Zhao Y, Dong B, Zhou Y, Lv W, Zhao W. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. J Diabetes Investig 2020;11:1238-47. [PMID: 32083798 DOI: 10.1111/jdi.13237] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
30 Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2010;103:71-83. [PMID: 19914930 DOI: 10.1093/qjmed/hcp158] [Cited by in Crossref: 392] [Cited by in F6Publishing: 366] [Article Influence: 30.2] [Reference Citation Analysis]
31 Cho KY, Nakamura A, Omori K, Takase T, Miya A, Yamamoto K, Nomoto H, Kameda H, Taneda S, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. J Diabetes Investig 2021;12:1272-7. [PMID: 33131199 DOI: 10.1111/jdi.13457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009;2009:831670. [PMID: 19753129 DOI: 10.1155/2009/831670] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 5.5] [Reference Citation Analysis]
33 Dongiovanni P, Romeo S, Valenti L. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. Biomed Res Int 2015;2015:460190. [PMID: 26273621 DOI: 10.1155/2015/460190] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 11.1] [Reference Citation Analysis]
34 McNear S, Harrison SA. Current status of therapy in nonalcoholic Fatty liver disease. Therap Adv Gastroenterol. 2009;2:29-43. [PMID: 21180532 DOI: 10.1177/1756283x08100327] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
35 Cusi K. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia. 2016;59:1112-1120. [PMID: 27101131 DOI: 10.1007/s00125-016-3952-1] [Cited by in Crossref: 83] [Cited by in F6Publishing: 71] [Article Influence: 13.8] [Reference Citation Analysis]
36 Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol 2018; 24(30): 3361-3373 [PMID: 30122876 DOI: 10.3748/wjg.v24.i30.3361] [Cited by in CrossRef: 159] [Cited by in F6Publishing: 131] [Article Influence: 39.8] [Reference Citation Analysis]
37 Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C. Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Dig Dis Sci 2016;61:2108-17. [PMID: 26825843 DOI: 10.1007/s10620-016-4044-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
38 Willy JA, Young SK, Stevens JL, Masuoka HC, Wek RC. CHOP links endoplasmic reticulum stress to NF-κB activation in the pathogenesis of nonalcoholic steatohepatitis. Mol Biol Cell 2015;26:2190-204. [PMID: 25904325 DOI: 10.1091/mbc.E15-01-0036] [Cited by in Crossref: 70] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
39 Lomonaco R, Godinez Leiva E, Bril F, Shrestha S, Mansour L, Budd J, Portillo Romero J, Schmidt S, Chang KL, Samraj G, Malaty J, Huber K, Bedossa P, Kalavalapalli S, Marte J, Barb D, Poulton D, Fanous N, Cusi K. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care 2021;44:399-406. [PMID: 33355256 DOI: 10.2337/dc20-1997] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
40 Prasoppokakorn T, Pitisuttithum P, Treeprasertsuk S. Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). J Clin Transl Hepatol 2021;9:939-46. [PMID: 34966657 DOI: 10.14218/JCTH.2021.00189] [Reference Citation Analysis]
41 Lee YM, Sutedja DS, Wai CT, Dan YY, Aung MO, Zhou L, Cheng CL, Wee A, Lim SG. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008;2:196-201. [PMID: 19669304 DOI: 10.1007/s12072-008-9058-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 3.5] [Reference Citation Analysis]
42 Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013;1281:106-122. [PMID: 23363012 DOI: 10.1111/nyas.12016] [Cited by in Crossref: 159] [Cited by in F6Publishing: 148] [Article Influence: 17.7] [Reference Citation Analysis]
43 Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2016;43:1109-23. [PMID: 27061197 DOI: 10.1111/apt.13620] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
44 Lin P, Lu J, Wang Y, Gu W, Yu J, Zhao R. Naturally Occurring Stilbenoid TSG Reverses Non-Alcoholic Fatty Liver Diseases via Gut-Liver Axis. PLoS One 2015;10:e0140346. [PMID: 26474417 DOI: 10.1371/journal.pone.0140346] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
45 Cazanave SC, Mott JL, Elmi NA, Bronk SF, Werneburg NW, Akazawa Y, Kahraman A, Garrison SP, Zambetti GP, Charlton MR, Gores GJ. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem 2009;284:26591-602. [PMID: 19638343 DOI: 10.1074/jbc.M109.022491] [Cited by in Crossref: 148] [Cited by in F6Publishing: 99] [Article Influence: 11.4] [Reference Citation Analysis]
46 European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts. 2016;9:65-90. [PMID: 27055256 DOI: 10.1159/000443344] [Cited by in Crossref: 129] [Cited by in F6Publishing: 119] [Article Influence: 21.5] [Reference Citation Analysis]
47 Lattuada G, Radaelli MG, De Cobelli F, Esposito A, Manzoni G, Perra S, Del Maschio A, Castoldi G, Perseghin G. Fasting Whole-Body Energy Homeostasis and Hepatic Energy Metabolism in Nondiabetic Humans with Fatty Liver. Oxid Med Cell Longev 2019;2019:9796175. [PMID: 31097978 DOI: 10.1155/2019/9796175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, Prentki M, Madiraju M, Jenkinson CP, Cersosimo E, Musi N, Defronzo RA. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. Diabetologia 2009;52:723-32. [PMID: 19169664 DOI: 10.1007/s00125-008-1256-9] [Cited by in Crossref: 94] [Cited by in F6Publishing: 90] [Article Influence: 7.2] [Reference Citation Analysis]
49 Chitturi S. Treatment options for nonalcoholic Fatty liver disease. Therap Adv Gastroenterol 2008;1:173-89. [PMID: 21180527 DOI: 10.1177/1756283X08096951] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
50 Karlas T, Petroff D, Garnov N, Böhm S, Tenckhoff H, Wittekind C, Wiese M, Schiefke I, Linder N, Schaudinn A. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One. 2014;9:e91987. [PMID: 24637477 DOI: 10.1371/journal.pone.0091987] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 10.0] [Reference Citation Analysis]
51 Moriya T, Kitamori K, Naito H, Yanagiba Y, Ito Y, Yamagishi N, Tamada H, Jia X, Tsuchikura S, Ikeda K, Yamori Y, Nakajima T. Simultaneous changes in high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis and those underlying molecular mechanisms in novel SHRSP5/Dmcr rat. Environ Health Prev Med 2012;17:444-56. [PMID: 22407906 DOI: 10.1007/s12199-012-0273-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
52 Lorenzo C, Hanley AJ, Rewers MJ, Haffner SM. Discriminatory value of alanine aminotransferase for diabetes prediction: the Insulin Resistance Atherosclerosis Study. Diabet Med 2016;33:348-55. [PMID: 26094705 DOI: 10.1111/dme.12835] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
53 Ohki T, Isogawa A, Toda N, Tagawa K. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors. Clin Drug Investig. 2016;36:313-319. [PMID: 26914659 DOI: 10.1007/s40261-016-0383-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
54 Mantovani A, Dalbeni A. Treatments for NAFLD: State of Art. Int J Mol Sci 2021;22:2350. [PMID: 33652942 DOI: 10.3390/ijms22052350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
55 Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021;18:599-612. [PMID: 33972770 DOI: 10.1038/s41575-021-00448-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
56 Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010;:CD007340. [PMID: 20091629 DOI: 10.1002/14651858.CD007340.pub2] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 8.3] [Reference Citation Analysis]
57 Chang E, Park CY, Park SW. Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J Diabetes Investig 2013;4:517-24. [PMID: 24843703 DOI: 10.1111/jdi.12107] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
58 Virtue S, Vidal-Puig A. It's not how fat you are, it's what you do with it that counts. PLoS Biol 2008;6:e237. [PMID: 18816166 DOI: 10.1371/journal.pbio.0060237] [Cited by in Crossref: 198] [Cited by in F6Publishing: 182] [Article Influence: 14.1] [Reference Citation Analysis]
59 Lomonaco R, Chen J, Cusi K. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Ther Adv Endocrinol Metab. 2011;2:211-225. [PMID: 23148186 DOI: 10.1177/2042018811419157] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
60 Witjes JJ, Smits LP, Pekmez CT, Prodan A, Meijnikman AS, Troelstra MA, Bouter KEC, Herrema H, Levin E, Holleboom AG, Winkelmeijer M, Beuers UH, van Lienden K, Aron-Wisnewky J, Mannisto V, Bergman JJ, Runge JH, Nederveen AJ, Dragsted LO, Konstanti P, Zoetendal EG, de Vos W, Verheij J, Groen AK, Nieuwdorp M. Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals With Steatohepatitis. Hepatol Commun 2020;4:1578-90. [PMID: 33163830 DOI: 10.1002/hep4.1601] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
61 Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Jsg-Nafld JSGON. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. Int J Mol Sci 2020;21:E1907. [PMID: 32168769 DOI: 10.3390/ijms21061907] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
62 Carr RM, Reid AE. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr Atheroscler Rep. 2015;17:500. [PMID: 25690590 DOI: 10.1007/s11883-015-0500-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 7.1] [Reference Citation Analysis]
63 Negrin KA, Roth Flach RJ, DiStefano MT, Matevossian A, Friedline RH, Jung D, Kim JK, Czech MP. IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis. PLoS One. 2014;9:e107265. [PMID: 25216251 DOI: 10.1371/journal.pone.0107265] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 8.3] [Reference Citation Analysis]
64 Akazawa Y, Cazanave S, Mott JL, Elmi N, Bronk SF, Kohno S, Charlton MR, Gores GJ. Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol. 2010;52:586-593. [PMID: 20206402 DOI: 10.1016/j.jhep.2010.01.003] [Cited by in Crossref: 151] [Cited by in F6Publishing: 143] [Article Influence: 12.6] [Reference Citation Analysis]
65 Huang YZ, Yang GY, Wang C, Chen XY, Zhang LL. Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis. World J Diabetes 2021; 12(9): 1576-1586 [PMID: 34630909 DOI: 10.4239/wjd.v12.i9.1576] [Reference Citation Analysis]
66 Johansson L, Hockings PD, Johnsson E, Dronamraju N, Maaske J, Garcia-Sanchez R, Wilding JPH. Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. Diabetes Obes Metab 2020;22:1094-101. [PMID: 32072735 DOI: 10.1111/dom.14004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
67 Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. Adv Ther 2009;26:893-907. [PMID: 19921118 DOI: 10.1007/s12325-009-0072-z] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 4.5] [Reference Citation Analysis]
68 Cho YK. Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone? Clin Mol Hepatol 2018;24:299-301. [PMID: 30196651 DOI: 10.3350/cmh.2018.1006] [Reference Citation Analysis]
69 Kho MC, Lee YJ, Park JH, Cha JD, Choi KM, Kang DG, Lee HS. Combination with Red ginseng and Polygoni Multiflori ameliorates highfructose diet induced metabolic syndrome. BMC Complement Altern Med 2016;16:98. [PMID: 26961224 DOI: 10.1186/s12906-016-1063-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
70 Tian YF, He CT, Chen YT, Hsieh PS. Lipoic acid suppresses portal endotoxemia-induced steatohepatitis and pancreatic inflammation in rats. World J Gastroenterol 2013; 19(18): 2761-2771 [PMID: 23687413 DOI: 10.3748/wjg.v19.i18.2761] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
71 Peng J, Huan Y, Jiang Q, Sun SJ, Jia CM, Shen ZF. Effects and Potential Mechanisms of Pioglitazone on Lipid Metabolism in Obese Diabetic KKAy Mice. PPAR Res 2014;2014:538183. [PMID: 24799887 DOI: 10.1155/2014/538183] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
72 Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, Abdelmalek MF, Harrison SA, Loomba R, Mantzoros CS, Bugianesi E, Eckel RH, Kaplan LM, El-Serag HB, Cusi K. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2021;161:1657-69. [PMID: 34602251 DOI: 10.1053/j.gastro.2021.07.049] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology. 2008;48:670-678. [PMID: 18666225 DOI: 10.1002/hep.22399] [Cited by in Crossref: 136] [Cited by in F6Publishing: 143] [Article Influence: 9.7] [Reference Citation Analysis]
74 Lemoine M, Capeau J, Serfaty L. PPAR and liver injury in HIV-infected patients. PPAR Res 2009;2009:906167. [PMID: 19390649 DOI: 10.1155/2009/906167] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
75 Nanthakumar CB, Hatley RJ, Lemma S, Gauldie J, Marshall RP, Macdonald SJ. Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nat Rev Drug Discov. 2015;14:693-720. [PMID: 26338155 DOI: 10.1038/nrd4592] [Cited by in Crossref: 131] [Cited by in F6Publishing: 120] [Article Influence: 18.7] [Reference Citation Analysis]
76 Simon TG, Chan AT. Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma. Clin Liver Dis 2020;24:549-76. [PMID: 33012445 DOI: 10.1016/j.cld.2020.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Marra F, Bertolani C, Aleffi S, Provenzano A, Vizzutti F. Cellular and molecular basis of fibrogenesis in NASH. Arab Journal of Gastroenterology 2010;10:S35-7. [DOI: 10.1016/j.ajg.2009.12.001] [Reference Citation Analysis]
78 Schindhelm RK, Diamant M, Heine RJ. Nonalcoholic fatty liver disease and cardiovascular disease risk. Curr Diab Rep 2007;7:181-7. [PMID: 17547835 DOI: 10.1007/s11892-007-0030-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
79 Abdul-Ghani MA, DeFronzo RA. Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus. Curr Diab Rep 2008;8:173-8. [PMID: 18625112 DOI: 10.1007/s11892-008-0030-1] [Cited by in Crossref: 95] [Cited by in F6Publishing: 82] [Article Influence: 6.8] [Reference Citation Analysis]
80 Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, Frier BM, Van Look LA, Johnston GI, Reynolds RM, Strachan MW;  Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011;34:1139-1144. [PMID: 21478462 DOI: 10.2337/dc10-2229] [Cited by in Crossref: 217] [Cited by in F6Publishing: 202] [Article Influence: 19.7] [Reference Citation Analysis]
81 Leonardini A, Laviola L, Perrini S, Natalicchio A, Giorgino F. Cross-Talk between PPARgamma and Insulin Signaling and Modulation of Insulin Sensitivity. PPAR Res. 2009;2009:818945. [PMID: 20182551 DOI: 10.1155/2009/818945] [Cited by in Crossref: 87] [Cited by in F6Publishing: 91] [Article Influence: 7.3] [Reference Citation Analysis]
82 Lidofsky SD. Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment. Curr Diab Rep. 2008;8:25-30. [PMID: 18366995 DOI: 10.1007/s11892-008-0006-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
83 Ohno T, Nishigaki Y, Yamada T, Wakahara Y, Sakai H, Yoshimura K, Shimizu M, Usui T, Saito M, Yasuda I, Tsurumi H, Tomita E, Moriwaki H. Effects of pioglitazone on nonalcoholic steatohepatitis in a patient with anorexia nervosa: A case report. Exp Ther Med 2014;7:811-5. [PMID: 24669237 DOI: 10.3892/etm.2014.1509] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
84 Cariou B, Hanf R, Lambert-Porcheron S, Zaïr Y, Sauvinet V, Noël B, Flet L, Vidal H, Staels B, Laville M. Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care. 2013;36:2923-2930. [PMID: 23715754 DOI: 10.2337/dc12-2012] [Cited by in Crossref: 150] [Cited by in F6Publishing: 144] [Article Influence: 16.7] [Reference Citation Analysis]
85 Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, Pirmohamed M, Kemp GJ. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One. 2012;7:e50117. [PMID: 23236362 DOI: 10.1371/journal.pone.0050117] [Cited by in Crossref: 138] [Cited by in F6Publishing: 134] [Article Influence: 13.8] [Reference Citation Analysis]
86 Matsusue K, Kusakabe T, Noguchi T, Takiguchi S, Suzuki T, Yamano S, Gonzalez FJ. Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. Cell Metab. 2008;7:302-311. [PMID: 18396136 DOI: 10.1016/j.cmet.2008.03.003] [Cited by in Crossref: 243] [Cited by in F6Publishing: 232] [Article Influence: 17.4] [Reference Citation Analysis]
87 Prieur X, Le May C, Magré J, Cariou B. Congenital lipodystrophies and dyslipidemias. Curr Atheroscler Rep 2014;16:437. [PMID: 25047893 DOI: 10.1007/s11883-014-0437-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
88 Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, Fischer W, Steiner F, Lindauer E, Otto M, Dreyhaupt J, Grehl T, Hermann A, Winkler AS, Bogdahn U, Benecke R, Schrank B, Wessig C, Grosskreutz J, Ludolph AC; GERP ALS Study Group. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One 2012;7:e37885. [PMID: 22715372 DOI: 10.1371/journal.pone.0037885] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 9.1] [Reference Citation Analysis]
89 Mills EP, Brown KPD, Smith JD, Vang PW, Trotta K. Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety. Ther Adv Endocrinol Metab 2018;9:15-28. [PMID: 29344336 DOI: 10.1177/2042018817741852] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
90 Ding C, Tang Y, Zhu W, Huang P, Lian P, Ran J, Huang X. Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis. Acta Diabetol. [DOI: 10.1007/s00592-021-01830-7] [Reference Citation Analysis]
91 Teodoro JS, Varela AT, Rolo AP, Palmeira CM. High-fat and obesogenic diets: current and future strategies to fight obesity and diabetes. Genes Nutr 2014;9:406. [PMID: 24842072 DOI: 10.1007/s12263-014-0406-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
92 Chowdhury TA, Grant P. Drug therapies in type 2 diabetes: an era of personalised medicine. Clin Med (Lond) 2016;16:441-7. [PMID: 27697806 DOI: 10.7861/clinmedicine.16-5-441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
93 Uchida D, Takaki A, Adachi T, Okada H. Beneficial and Paradoxical Roles of Anti-Oxidative Nutritional Support for Non-Alcoholic Fatty Liver Disease. Nutrients 2018;10:E977. [PMID: 30060482 DOI: 10.3390/nu10080977] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
94 Kwak KA, Cho HJ, Yang JY, Park YS. Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis. Can J Gastroenterol Hepatol. 2018;2018:4197857. [PMID: 29670867 DOI: 10.1155/2018/4197857] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
95 Dubois V, Eeckhoute J, Lefebvre P, Staels B. Distinct but complementary contributions of PPAR isotypes to energy homeostasis. J Clin Invest 2017;127:1202-14. [PMID: 28368286 DOI: 10.1172/JCI88894] [Cited by in Crossref: 142] [Cited by in F6Publishing: 72] [Article Influence: 28.4] [Reference Citation Analysis]
96 Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD; ACT NOW Study. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes 2013;62:3920-6. [PMID: 23863810 DOI: 10.2337/db13-0265] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 6.4] [Reference Citation Analysis]
97 Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care 2017;40:813-20. [PMID: 28637886 DOI: 10.2337/dc16-2736] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 12.4] [Reference Citation Analysis]
98 Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, Dhiman RK, Jayakumar RV, Madan K, Misra SP, Mishra H, Modi SK, Muruganathan A, Saboo B, Sahay R, Upadhyay R. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J ClinExpHepatol. 2015;5:51-68. [PMID: 25941433 DOI: 10.1016/j.jceh.2015.02.006] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 9.9] [Reference Citation Analysis]
99 Sekhon AK, Gollapalli A, Kaur D, Janssen B, Stevens ML, Valerio F, Sierra-Hoffman MA. A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH). Am J Case Rep 2021;22:e932961. [PMID: 34826302 DOI: 10.12659/AJCR.932961] [Reference Citation Analysis]
100 Mehta SR, Thomas EL, Bell JD, Johnston DG, Taylor-Robinson SD. Non-invasive means of measuring hepatic fat content. World J Gastroenterol 2008; 14(22): 3476-3483 [PMID: 18567074 DOI: 10.3748/wjg.14.3476] [Cited by in CrossRef: 169] [Cited by in F6Publishing: 158] [Article Influence: 12.1] [Reference Citation Analysis]
101 Gregor MF, Yang L, Fabbrini E, Mohammed BS, Eagon JC, Hotamisligil GS, Klein S. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes 2009;58:693-700. [PMID: 19066313 DOI: 10.2337/db08-1220] [Cited by in Crossref: 333] [Cited by in F6Publishing: 313] [Article Influence: 23.8] [Reference Citation Analysis]
102 Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(45): 16841-16857 [PMID: 25492998 DOI: 10.3748/wjg.v20.i45.16841] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
103 Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int J Mol Sci 2021;22:5375. [PMID: 34065331 DOI: 10.3390/ijms22105375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Ozaki A, Yoneda M, Kessoku T, Iwaki M, Kobayashi T, Honda Y, Ogawa Y, Imajo K, Sakai E, Taguri M, Yamanaka T, Iwasaki T, Kurihashi T, Saito S, Nakajima A. Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study). Contemp Clin Trials Commun 2020;17:100516. [PMID: 31956725 DOI: 10.1016/j.conctc.2019.100516] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
105 Krakoff J, Clark JM, Crandall JP, Wilson C, Molitch ME, Brancati FL, Edelstein SL, Knowler WC; Diabetes Prevention Program Research Group. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring) 2010;18:1762-7. [PMID: 20186137 DOI: 10.1038/oby.2010.21] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
106 Jiang ZG, Robson SC, Yao Z. Lipoprotein metabolism in nonalcoholic fatty liver disease. J Biomed Res. 2013;27:1-13. [PMID: 23554788 DOI: 10.7555/jbr.27.20120077] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
107 Rockey DC. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 2008;12:939-62, xi. [PMID: 18984475 DOI: 10.1016/j.cld.2008.07.011] [Cited by in Crossref: 112] [Cited by in F6Publishing: 108] [Article Influence: 8.6] [Reference Citation Analysis]
108 Ipsen EØ, Madsen KS, Chi Y, Pedersen-Bjergaard U, Richter B, Metzendorf MI, Hemmingsen B. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 2020;11:CD013516. [PMID: 33210751 DOI: 10.1002/14651858.CD013516.pub2] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
109 Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009;32:187-202. [PMID: 19338377 DOI: 10.2165/00002018-200932030-00002] [Cited by in Crossref: 162] [Cited by in F6Publishing: 143] [Article Influence: 12.5] [Reference Citation Analysis]
110 Cazanave SC, Mott JL, Bronk SF, Werneburg NW, Fingas CD, Meng XW, Finnberg N, El-Deiry WS, Kaufmann SH, Gores GJ. Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem. 2011;286:39336-39348. [PMID: 21941003 DOI: 10.1074/jbc.m111.280420] [Cited by in Crossref: 83] [Cited by in F6Publishing: 55] [Article Influence: 7.5] [Reference Citation Analysis]
111 Li J, Tuo B. Current and Emerging Approaches for Hepatic Fibrosis Treatment. Gastroenterol Res Pract 2021;2021:6612892. [PMID: 34326871 DOI: 10.1155/2021/6612892] [Reference Citation Analysis]
112 Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009;49:306-17. [PMID: 19065650 DOI: 10.1002/hep.22603] [Cited by in Crossref: 372] [Cited by in F6Publishing: 347] [Article Influence: 28.6] [Reference Citation Analysis]
113 Kim H, Lee DS, An TH, Park HJ, Kim WK, Bae KH, Oh KJ. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. Int J Mol Sci 2021;22:4495. [PMID: 33925827 DOI: 10.3390/ijms22094495] [Reference Citation Analysis]
114 Masuoka HC, Mott J, Bronk SF, Werneburg NW, Akazawa Y, Kaufmann SH, Gores GJ. Mcl-1 degradation during hepatocyte lipoapoptosis. J Biol Chem 2009;284:30039-48. [PMID: 19734538 DOI: 10.1074/jbc.M109.039545] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
115 Coletta DK, Fernandez M, Cersosimo E, Gastaldelli A, Musi N, DeFronzo RA. The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo. Diabet Med 2015;32:657-64. [PMID: 25484175 DOI: 10.1111/dme.12664] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
116 Caldwell S. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. Clin Mol Hepatol 2017;23:103-8. [PMID: 28494529 DOI: 10.3350/cmh.2017.0103] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
117 Chen XJ, Ma LQ. Role of farnesoid X receptor in nonalcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2015; 23(8): 1258-1265 [DOI: 10.11569/wcjd.v23.i8.1258] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
118 Chen A, Tang Y, Davis V, Hsu FF, Kennedy SM, Song H, Turk J, Brunt EM, Newberry EP, Davidson NO. Liver fatty acid binding protein (L-Fabp) modulates murine stellate cell activation and diet-induced nonalcoholic fatty liver disease. Hepatology 2013;57:2202-12. [PMID: 23401290 DOI: 10.1002/hep.26318] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
119 Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 2014;20:573-91. [PMID: 25242225 DOI: 10.1016/j.cmet.2014.08.005] [Cited by in Crossref: 269] [Cited by in F6Publishing: 249] [Article Influence: 33.6] [Reference Citation Analysis]
120 Le TA, Loomba R. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. J Clin Exp Hepatol 2012;2:156-73. [PMID: 25755424 DOI: 10.1016/S0973-6883(12)60104-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
121 Sanai FM, Abaalkhail F, Hasan F, Farooqi MH, Nahdi NA, Younossi ZM. Management of nonalcoholic fatty liver disease in the Middle East. World J Gastroenterol 2020; 26(25): 3528-3541 [PMID: 32742124 DOI: 10.3748/wjg.v26.i25.3528] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 Vuppalanchi R, Unalp A, Van Natta ML, Cummings OW, Sandrasegaran KE, Hameed T, Tonascia J, Chalasani N. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol 2009;7:481-6. [PMID: 19162235 DOI: 10.1016/j.cgh.2008.12.015] [Cited by in Crossref: 110] [Cited by in F6Publishing: 102] [Article Influence: 7.9] [Reference Citation Analysis]
123 Blazer-Yost BL, Haydon J, Eggleston-Gulyas T, Chen JH, Wang X, Gattone V, Torres VE. Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease. PPAR Res 2010;2010:274376. [PMID: 21052534 DOI: 10.1155/2010/274376] [Cited by in Crossref: 23] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
124 Wiegand J, Mössner J, Tillmann HL. [Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis]. Internist (Berl) 2007;48:154-63. [PMID: 17226007 DOI: 10.1007/s00108-006-1796-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
125 Somi MH, Fatahi E, Panahi J, Havasian MR, Judaki A. Data from a randomized and controlled trial of LCarnitine prescription for the treatment for Non- Alcoholic Fatty Liver Disease. Bioinformation. 2014;10:575-579. [PMID: 25352725 DOI: 10.6026/97320630010575] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
126 Nishimiya N, Tajima K, Imajo K, Kameda A, Yoshida E, Togashi Y, Aoki K, Inoue T, Nakajima A, Utsunomiya D, Terauchi Y. Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease. Intern Med 2021;60:3391-9. [PMID: 33994437 DOI: 10.2169/internalmedicine.7134-21] [Reference Citation Analysis]
127 Francque S, Vonghia L. Pharmacological Treatment for Non-alcoholic Fatty Liver Disease. Adv Ther 2019;36:1052-74. [PMID: 30888594 DOI: 10.1007/s12325-019-00898-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
128 Springer F, Machann J, Claussen CD, Schick F, Schwenzer NF. Liver fat content determined by magnetic resonance imaging and spectroscopy. World J Gastroenterol 2010; 16(13): 1560-1566 [PMID: 20355234 DOI: 10.3748/wjg.v16.i13.1560] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 66] [Article Influence: 6.3] [Reference Citation Analysis]
129 Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-9. [PMID: 19827166 DOI: 10.1002/hep.23276] [Cited by in Crossref: 737] [Cited by in F6Publishing: 661] [Article Influence: 61.4] [Reference Citation Analysis]
130 Cauchy F, Fuks D, Zarzavadjian Le Bian A, Belghiti J, Costi R. Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges? World J Hepatol 2014; 6(5): 306-314 [PMID: 24868324 DOI: 10.4254/wjh.v6.i5.306] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
131 Wei Q, Xu X, Guo L, Li J, Li L. Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Front Endocrinol (Lausanne) 2021;12:635556. [PMID: 34220701 DOI: 10.3389/fendo.2021.635556] [Reference Citation Analysis]
132 Okazaki I, Noro T, Tsutsui N, Yamanouchi E, Kuroda H, Nakano M, Yokomori H, Inagaki Y. Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs). Cancers (Basel). 2014;6:1220-1255. [PMID: 24978432 DOI: 10.3390/cancers6031220] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
133 Boursier J, Anty R, Carette C, Cariou B, Castera L, Caussy C, Fontaine H, Garioud A, Gourdy P, Guerci B, Guillaume M, Michot N, Minello A, Ouizeman DJ, Serfaty L, Bonnet F, Vergès B, Petit JM; AFEF and SFD. Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. Diabetes Metab 2021;47:101272. [PMID: 34363981 DOI: 10.1016/j.diabet.2021.101272] [Reference Citation Analysis]
134 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14:32-42. [PMID: 27729660 DOI: 10.1038/nrgastro.2016.147] [Cited by in Crossref: 329] [Cited by in F6Publishing: 309] [Article Influence: 54.8] [Reference Citation Analysis]
135 Perumpail RB, Wong RJ, Ahmed A, Harrison SA. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Dig Dis Sci. 2015;60:3142-3148. [PMID: 26250831 DOI: 10.1007/s10620-015-3821-7] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 9.0] [Reference Citation Analysis]
136 Schlegel A. Studying non-alcoholic fatty liver disease with zebrafish: a confluence of optics, genetics, and physiology. Cell Mol Life Sci 2012;69:3953-61. [PMID: 22678663 DOI: 10.1007/s00018-012-1037-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
137 Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs. 2013;73:1-14. [PMID: 23329465 DOI: 10.1007/s40265-012-0004-0] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 11.7] [Reference Citation Analysis]
138 Nobili V, Manco M. Therapeutic strategies for pediatric non-alcoholic fatty liver disease: A challenge for health care providers. World J Gastroenterol 2007; 13(18): 2639-2641 [PMID: 17552019 DOI: 10.3748/wjg.v13.i18.2639] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
139 Triplitt C, Cersosimo E, DeFronzo RA. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vasc Health Risk Manag 2010;6:671-90. [PMID: 20859539 DOI: 10.2147/vhrm.s4852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
140 Taylor R. Type 2 diabetes: etiology and reversibility. Diabetes Care. 2013;36:1047-1055. [PMID: 23520370 DOI: 10.2337/dc12-1805] [Cited by in Crossref: 172] [Cited by in F6Publishing: 135] [Article Influence: 19.1] [Reference Citation Analysis]
141 Uchida D, Takaki A, Oyama A, Adachi T, Wada N, Onishi H, Okada H. Oxidative Stress Management in Chronic Liver Diseases and Hepatocellular Carcinoma. Nutrients 2020;12:E1576. [PMID: 32481552 DOI: 10.3390/nu12061576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
142 Villareal DT, Koster JC, Robertson H, Akrouh A, Miyake K, Bell GI, Patterson BW, Nichols CG, Polonsky KS. Kir6.2 variant E23K increases ATP-sensitive K+ channel activity and is associated with impaired insulin release and enhanced insulin sensitivity in adults with normal glucose tolerance. Diabetes 2009;58:1869-78. [PMID: 19491206 DOI: 10.2337/db09-0025] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 4.7] [Reference Citation Analysis]
143 Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010;3:121-37. [PMID: 21180596 DOI: 10.1177/1756283X09359964] [Cited by in Crossref: 70] [Cited by in F6Publishing: 40] [Article Influence: 6.4] [Reference Citation Analysis]
144 Takahashi Y, Fukusato T. Pediatric nonalcoholic fatty liver disease: Overview with emphasis on histology. World J Gastroenterol 2010; 16(42): 5280-5285 [PMID: 21072890 DOI: 10.3748/wjg.v16.i42.5280] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
145 Kim KS, Lee BW. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26:430-43. [PMID: 32791578 DOI: 10.3350/cmh.2020.0137] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
146 Paniagua JA. Nutrition, insulin resistance and dysfunctional adipose tissue determine the different components of metabolic syndrome. World J Diabetes 2016; 7(19): 483-514 [PMID: 27895819 DOI: 10.4239/wjd.v7.i19.483] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 60] [Article Influence: 11.3] [Reference Citation Analysis]
147 Amirinejad A, Totmaj AS, Mardali F, Hekmatdoost A, Emamat H, Safa M, Shidfar F. Administration of hydro-alcoholic extract of spinach improves oxidative stress and inflammation in high-fat diet-induced NAFLD rats. BMC Complement Med Ther 2021;21:221. [PMID: 34479550 DOI: 10.1186/s12906-021-03396-x] [Reference Citation Analysis]
148 Dinani A, Sanyal A. Nonalcoholic fatty liver disease: implications for cardiovascular risk. Cardiovasc Endocrinol 2017;6:62-72. [PMID: 31646122 DOI: 10.1097/XCE.0000000000000126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
149 Wang YL, Liu LJ, Zhao WH, Li JX. Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med. 2015;2015:715638. [PMID: 26221176 DOI: 10.1155/2015/715638] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
150 Beuers U, Kullak-Ublick GA, Pusl T, Rauws ER, Rust C. Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators? Clin Rev Allergy Immunol 2009;36:52-61. [PMID: 18751930 DOI: 10.1007/s12016-008-8085-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
151 Hu YB. Mechanisms of non-alcoholic steatohepatitis: pathophysiology and molecular biology. Shijie Huaren Xiaohua Zazhi 2009; 17(13): 1329-1334 [DOI: 10.11569/wcjd.v17.i13.1329] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
152 Di Pino A, DeFronzo RA. Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocr Rev 2019;40:1447-67. [PMID: 31050706 DOI: 10.1210/er.2018-00141] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 25.5] [Reference Citation Analysis]
153 Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Hecht J, Tio F, Cusi K. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.J Clin Endocrinol Metab. 2017;102:2950-2961. [PMID: 28575232 DOI: 10.1210/jc.2017-00867] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
154 Leamy AK, Egnatchik RA, Young JD. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res 2013;52:165-74. [PMID: 23178552 DOI: 10.1016/j.plipres.2012.10.004] [Cited by in Crossref: 232] [Cited by in F6Publishing: 231] [Article Influence: 23.2] [Reference Citation Analysis]
155 Cho IJ, Oh DH, Yoo J, Hwang YC, Ahn KJ, Chung HY, Jeong SW, Moon JY, Lee SH, Lim SJ, Jeong IK. Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway. Sci Rep 2021;11:9894. [PMID: 33972568 DOI: 10.1038/s41598-021-88872-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology. 2014;147:765-783.e4. [PMID: 25046161 DOI: 10.1053/j.gastro.2014.07.018] [Cited by in Crossref: 365] [Cited by in F6Publishing: 350] [Article Influence: 45.6] [Reference Citation Analysis]
157 Domínguez M, Colmenero J, Bataller R. Tratamiento de la fibrosis hepática. Gastroenterología y Hepatología 2009;32:627-32. [DOI: 10.1016/j.gastrohep.2009.02.015] [Reference Citation Analysis]
158 Mangi MA, Rehman H, Minhas AM, Rafique M, Bansal V, Constantin J. Non-Alcoholic Fatty Liver Disease Association with Cardiac Arrhythmias. Cureus 2017;9:e1165. [PMID: 28507837 DOI: 10.7759/cureus.1165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
159 Pola A, Sadananthan SA, Gopalan V, Tan ML, Keong TY, Zhou Z, Ishino S, Nakano Y, Watanabe M, Horiguchi T, Nishimoto T, Zhu B, Velan SS. Investigation of Fat Metabolism during Antiobesity Interventions by Magnetic Resonance Imaging and Spectroscopy. Magn Reson Insights 2014;7:33-40. [PMID: 25574137 DOI: 10.4137/MRI.S19362] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
160 Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, Modi A, Nagabhyru P, Sumner AE, Liang TJ, Hoofnagle JH. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2009;29:172-182. [PMID: 18945255 DOI: 10.1111/j.1365-2036.2008.03869.x] [Cited by in Crossref: 174] [Cited by in F6Publishing: 161] [Article Influence: 12.4] [Reference Citation Analysis]
161 Khavasi N, Somi MH, Khadem E, Faramarzi E, Ayati MH, Fazljou SMB, Torbati M. Effect of Daily Caper Fruit Pickle Consumption on Disease Regression in Patients with Non-Alcoholic Fatty Liver Disease: a Double-Blinded Randomized Clinical Trial. Adv Pharm Bull 2017;7:645-50. [PMID: 29399555 DOI: 10.15171/apb.2017.077] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
162 Gitto S, Vitale G, Villa E, Andreone P. Treatment of nonalcoholic steatohepatitis in adults: present and future. Gastroenterol Res Pract. 2015;2015:732870. [PMID: 25866507 DOI: 10.1155/2015/732870] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
163 Saponaro C, Gaggini M, Carli F, Gastaldelli A. The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis. Nutrients 2015;7:9453-74. [PMID: 26580649 DOI: 10.3390/nu7115475] [Cited by in Crossref: 197] [Cited by in F6Publishing: 188] [Article Influence: 28.1] [Reference Citation Analysis]
164 Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53:362-376. [PMID: 29247356 DOI: 10.1007/s00535-017-1415-1] [Cited by in Crossref: 227] [Cited by in F6Publishing: 214] [Article Influence: 45.4] [Reference Citation Analysis]
165 Borbath I, Horsmans Y. The Role of PPARgamma in Hepatocellular Carcinoma. PPAR Res 2008;2008:209520. [PMID: 18509497 DOI: 10.1155/2008/209520] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
166 Blazina I, Selph S. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. Syst Rev 2019;8:295. [PMID: 31783920 DOI: 10.1186/s13643-019-1200-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
167 Jeong JY, Sohn JH, Baek YH, Cho YK, Kim Y, Kim H. New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: A placebo-controlled, randomized, phase II trial. World J Gastroenterol 2017; 23(32): 5977-5985 [PMID: 28932090 DOI: 10.3748/wjg.v23.i32.5977] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
168 Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, Sanyal AJ, Kowdley KV, Neuschwander-Tetri BA, Brunt EM. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology. 2012;56:1311-1318. [PMID: 22532269 DOI: 10.1002/hep.25805] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 6.4] [Reference Citation Analysis]
169 Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J. Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. J Clin Transl Hepatol 2017;5:67-75. [PMID: 28507929 DOI: 10.14218/JCTH.2016.00061] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
170 Marušić M, Paić M, Knobloch M, Liberati Pršo AM. NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. Can J Gastroenterol Hepatol 2021;2021:6613827. [PMID: 33681089 DOI: 10.1155/2021/6613827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
171 Rawlins SR, El-Zammar O, Zinkievich JM, Newman N, Levine RA. Digital quantification is more precise than traditional semiquantitation of hepatic steatosis: correlation with fibrosis in 220 treatment-naïve patients with chronic hepatitis C. Dig Dis Sci 2010;55:2049-57. [PMID: 20458626 DOI: 10.1007/s10620-010-1254-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
172 Ben MD, Polimeni L, Baratta F, Pastori D, Loffredo L, Angelico F. Modern approach to the clinical management of non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(26): 8341-8350 [PMID: 25024593 DOI: 10.3748/wjg.v20.i26.8341] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 46] [Article Influence: 5.5] [Reference Citation Analysis]
173 González-Rodríguez A, Mayoral R, Agra N, Valdecantos MP, Pardo V, Miquilena-Colina ME, Vargas-Castrillón J, Lo Iacono O, Corazzari M, Fimia GM. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. Cell Death Dis. 2014;5:e1179. [PMID: 24743734 DOI: 10.1038/cddis.2014.162] [Cited by in Crossref: 287] [Cited by in F6Publishing: 281] [Article Influence: 35.9] [Reference Citation Analysis]
174 Cusi K. Diabetes medications improve cardiovascular outcomes: the paradigm shifts. Curr Opin Lipidol 2016;27:633-5. [PMID: 27805974 DOI: 10.1097/MOL.0000000000000361] [Reference Citation Analysis]
175 Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. J Lipid Res 2011;52:593-617. [PMID: 21245030 DOI: 10.1194/jlr.R008896] [Cited by in Crossref: 83] [Cited by in F6Publishing: 55] [Article Influence: 7.5] [Reference Citation Analysis]
176 Roden M. Hepatic glucose production and insulin resistance. Wien Med Wochenschr. 2008;158:558-561. [PMID: 18998072 DOI: 10.1007/s10354-008-0595-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
177 Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX. Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. Front Pharmacol 2020;11:603926. [PMID: 33343375 DOI: 10.3389/fphar.2020.603926] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
178 Jia C, Huan Y, Liu S, Hou S, Sun S, Li C, Liu Q, Jiang Q, Wang Y, Shen Z. Effect of Chronic Pioglitazone Treatment on Hepatic Gene Expression Profile in Obese C57BL/6J Mice. Int J Mol Sci 2015;16:12213-29. [PMID: 26035752 DOI: 10.3390/ijms160612213] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
179 Liu Q, Izamis ML, Xu H, Berendsen T, Yarmush M, Uygun K. Strategies to rescue steatotic livers before transplantation in clinical and experimental studies. World J Gastroenterol 2013; 19(29): 4638-4650 [PMID: 23922462 DOI: 10.3748/wjg.v19.i29.4638] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
180 Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2011;8:92-103. [PMID: 21912398 DOI: 10.1038/nrendo.2011.138] [Cited by in Crossref: 333] [Cited by in F6Publishing: 310] [Article Influence: 30.3] [Reference Citation Analysis]
181 Wong CR, Lim JK. The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes: NAFLD and Cardiovascular Disease Outcomes. Clinical Liver Disease 2018;12:39-44. [DOI: 10.1002/cld.721] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
182 Bhatt SP, Guleria R. Sleep apnea and fatty liver disease: The growing link and management issues. World J Respirol 2014; 4(2): 11-18 [DOI: 10.5320/wjr.v4.i2.11] [Cited by in CrossRef: 2] [Article Influence: 0.3] [Reference Citation Analysis]
183 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
184 Peng J, Li Q, Li K, Zhu L, Lin X, Lin X, Shen Q, Li G, Xie X. Quercetin Improves Glucose and Lipid Metabolism of Diabetic Rats: Involvement of Akt Signaling and SIRT1. J Diabetes Res 2017;2017:3417306. [PMID: 29379801 DOI: 10.1155/2017/3417306] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 9.0] [Reference Citation Analysis]
185 Chung W, Promrat K, Wands J. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. World J Hepatol 2020; 12(9): 533-557 [PMID: 33033564 DOI: 10.4254/wjh.v12.i9.533] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
186 Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci. 2013;14:22933-22966. [PMID: 24264040 DOI: 10.3390/ijms141122933] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 6.9] [Reference Citation Analysis]
187 Gastaldelli A, Stefan N, Häring HU. Liver-targeting drugs and their effect on blood glucose and hepatic lipids. Diabetologia 2021;64:1461-79. [PMID: 33877366 DOI: 10.1007/s00125-021-05442-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
188 Schrader M, Fahimi HD. The peroxisome: still a mysterious organelle. Histochem Cell Biol 2008;129:421-40. [PMID: 18274771 DOI: 10.1007/s00418-008-0396-9] [Cited by in Crossref: 124] [Cited by in F6Publishing: 115] [Article Influence: 8.9] [Reference Citation Analysis]
189 Dawson AJ, Kilpatrick ES, Coady AM, Elshewehy AMM, Dakroury Y, Ahmed L, Atkin SL, Sathyapalan T. Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. BMC Endocr Disord 2017;17:41. [PMID: 28705172 DOI: 10.1186/s12902-017-0194-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
190 Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, Unalp A, Tonascia J. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials. 2009;30:88-96. [PMID: 18804555 DOI: 10.1016/j.cct.2008.09.00] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
191 He L, Liu X, Wang L, Yang Z. Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials. Medicine (Baltimore) 2016;95:e4947. [PMID: 27759627 DOI: 10.1097/MD.0000000000004947] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
192 Tsoulfas G. Hepatocellular carcinoma and metabolic syndrome: The times are changing and so should we. World J Gastroenterol 2019; 25(29): 3842-3848 [PMID: 31413522 DOI: 10.3748/wjg.v25.i29.3842] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
193 Vander Naalt SJ, Gurria JP, Holterman AL. Surgical treatment of nonalcoholic fatty liver disease in severely obese patients. Hepat Med 2014;6:103-12. [PMID: 25378958 DOI: 10.2147/HMER.S64819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
194 Gusdon AM, Song KX, Qu S. Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. Oxid Med Cell Longev 2014;2014:637027. [PMID: 25371775 DOI: 10.1155/2014/637027] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 10.9] [Reference Citation Analysis]
195 Loomba R, Sirlin CB, Ang B, Bettencourt R, Jain R, Salotti J, Soaft L, Hooker J, Kono Y, Bhatt A, Hernandez L, Nguyen P, Noureddin M, Haufe W, Hooker C, Yin M, Ehman R, Lin GY, Valasek MA, Brenner DA, Richards L; San Diego Integrated NAFLD Research Consortium (SINC). Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology. 2015;61:1239-1250. [PMID: 25482832 DOI: 10.1002/hep.27647] [Cited by in Crossref: 216] [Cited by in F6Publishing: 209] [Article Influence: 30.9] [Reference Citation Analysis]
196 Lombardi R, Onali S, Thorburn D, Davidson BR, Gurusamy KS, Tsochatzis E. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011640. [PMID: 28358980 DOI: 10.1002/14651858.CD011640.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
197 Wang W, Xu MJ, Cai Y, Zhou Z, Cao H, Mukhopadhyay P, Pacher P, Zheng S, Gonzalez FJ, Gao B. Inflammation is independent of steatosis in a murine model of steatohepatitis. Hepatology 2017;66:108-23. [PMID: 28220523 DOI: 10.1002/hep.29129] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 7.6] [Reference Citation Analysis]
198 Heinrich S, Lang H. Primäre Lebertumoren: Präoperative Konditionierung der Leber und perioperatives Management bei erweiterten Leberresektionen. Chirurg 2015;86:125-31. [DOI: 10.1007/s00104-014-2881-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
199 Dixon ED, Nardo AD, Claudel T, Trauner M. The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD. Genes (Basel) 2021;12:645. [PMID: 33926085 DOI: 10.3390/genes12050645] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
200 Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A, Klein S. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A 2009;106:15430-5. [PMID: 19706383 DOI: 10.1073/pnas.0904944106] [Cited by in Crossref: 629] [Cited by in F6Publishing: 600] [Article Influence: 48.4] [Reference Citation Analysis]
201 Wolf Greenstein A, Majumdar N, Yang P, Subbaiah PV, Kineman RD, Cordoba-Chacon J. Hepatocyte-specific, PPARγ-regulated mechanisms to promote steatosis in adult mice. J Endocrinol 2017;232:107-21. [PMID: 27799461 DOI: 10.1530/JOE-16-0447] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
202 Samuel VT, Shulman GI. Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. Cell Metab 2018;27:22-41. [PMID: 28867301 DOI: 10.1016/j.cmet.2017.08.002] [Cited by in Crossref: 234] [Cited by in F6Publishing: 224] [Article Influence: 46.8] [Reference Citation Analysis]
203 Ertunc ME, Hotamisligil GS. Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment. J Lipid Res. 2016;57:2099-2114. [PMID: 27330055 DOI: 10.1194/jlr.r066514] [Cited by in Crossref: 209] [Cited by in F6Publishing: 108] [Article Influence: 34.8] [Reference Citation Analysis]
204 Sakhaee K. Pharmacology of stone disease. Adv Chronic Kidney Dis 2009;16:30-8. [PMID: 19095203 DOI: 10.1053/j.ackd.2008.10.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
205 Gatselis NK, Ntaios G, Makaritsis K, Dalekos GN. Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. Clin Exp Med. 2014;14:121-131. [PMID: 23292294 DOI: 10.1007/s10238-012-0227-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
206 Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85. [PMID: 20427778 DOI: 10.1056/NEJMoa0907929] [Cited by in Crossref: 1821] [Cited by in F6Publishing: 871] [Article Influence: 151.8] [Reference Citation Analysis]
207 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell'Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Dig Liver Dis 2021:S1590-8658(21)00214-0. [PMID: 34924319 DOI: 10.1016/j.dld.2021.04.029] [Reference Citation Analysis]
208 Ota T. Immune regulation of glucose and lipid metabolism. Diabetol Int 2017;8:257-67. [PMID: 30603331 DOI: 10.1007/s13340-017-0331-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
209 Gawrieh S, Marion MC, Komorowski R, Wallace J, Charlton M, Kissebah A, Langefeld CD, Olivier M. Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Dig Dis Sci. 2012;57:952-957. [PMID: 22160635 DOI: 10.1007/s10620-011-1994-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
210 Ibrahim SH, Akazawa Y, Cazanave SC, Bronk SF, Elmi NA, Werneburg NW, Billadeau DD, Gores GJ. Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis. J Hepatol. 2011;54:765-772. [PMID: 21147505 DOI: 10.1016/j.jhep.2010.09.039] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
211 Nishi T, Babazono A, Maeda T, Imatoh T, Une H. Evaluation of the fatty liver index as a predictor for the development of diabetes among insurance beneficiaries with prediabetes. J Diabetes Investig 2015;6:309-16. [PMID: 25969716 DOI: 10.1111/jdi.12290] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
212 Kashyap SR, Diab DL, Baker AR, Yerian L, Bajaj H, Gray-McGuire C, Schauer PR, Gupta M, Feldstein AE, Hazen SL. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity (Silver Spring). 2009;17:1696-1701. [PMID: 19360015 DOI: 10.1038/oby.2009.89] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
213 Carrion AF, Ghanta R, Carrasquillo O, Martin P. Chronic liver disease in the Hispanic population of the United States. Clin Gastroenterol Hepatol 2011;9:834-41; quiz e109-10. [PMID: 21628000 DOI: 10.1016/j.cgh.2011.04.027] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 5.7] [Reference Citation Analysis]
214 Banini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clin Med Insights Ther 2016;8:75-84. [PMID: 28670148 DOI: 10.4137/cmt.s18885] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
215 Kantartzis K, Machann J, Schick F, Fritsche A, Häring HU, Stefan N. The impact of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia. 2010;53:882-889. [PMID: 20099057 DOI: 10.1007/s00125-010-1663-6] [Cited by in Crossref: 103] [Cited by in F6Publishing: 92] [Article Influence: 8.6] [Reference Citation Analysis]
216 Hwang YC, Oh DH, Choi MC, Lee SY, Ahn KJ, Chung HY, Lim SJ, Chung SH, Jeong IK. Compound K attenuates glucose intolerance and hepatic steatosis through AMPK-dependent pathways in type 2 diabetic OLETF rats. Korean J Intern Med 2018;33:347-55. [PMID: 28142230 DOI: 10.3904/kjim.2015.208] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
217 Han E, Lee YH, Lee BW, Kang ES, Cha BS. Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial. J Clin Med 2020;9:E259. [PMID: 31963648 DOI: 10.3390/jcm9010259] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
218 Sun Y, Yuan X, Zhang F, Han Y, Chang X, Xu X, Li Y, Gao X. Berberine ameliorates fatty acid-induced oxidative stress in human hepatoma cells. Sci Rep 2017;7:11340. [PMID: 28900305 DOI: 10.1038/s41598-017-11860-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
219 Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep 2019;1:312-28. [PMID: 32039382 DOI: 10.1016/j.jhepr.2019.07.002] [Cited by in Crossref: 81] [Cited by in F6Publishing: 65] [Article Influence: 27.0] [Reference Citation Analysis]
220 Adams LA, Angulo P, Petz J, Keach J, Lindor KD. A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. Hepatol Int 2010;4:628-33. [PMID: 21063487 DOI: 10.1007/s12072-010-9195-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
221 Tarantino G. Is Assessing the Presence of NASH by Liver Histology or Surrogate Markers Always Advisable? Hepat Mon. 2013;13:e7560. [PMID: 23610586 DOI: 10.5812/hepatmon.7560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
222 Hsiao PJ, Hsieh TJ, Kuo KK, Hung WW, Tsai KB, Yang CH, Yu ML, Shin SJ. Pioglitazone retrieves hepatic antioxidant DNA repair in a mice model of high fat diet. BMC Mol Biol 2008;9:82. [PMID: 18822121 DOI: 10.1186/1471-2199-9-82] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
223 Min-DeBartolo J, Schlerman F, Akare S, Wang J, McMahon J, Zhan Y, Syed J, He W, Zhang B, Martinez RV. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH). PLoS One 2019;14:e0226854. [PMID: 31891606 DOI: 10.1371/journal.pone.0226854] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
224 Polotsky VY, Patil SP, Savransky V, Laffan A, Fonti S, Frame LA, Steele KE, Schweizter MA, Clark JM, Torbenson MS. Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. Am J Respir Crit Care Med. 2009;179:228-234. [PMID: 18990675 DOI: 10.1164/rccm.200804-608oc] [Cited by in Crossref: 124] [Cited by in F6Publishing: 65] [Article Influence: 8.9] [Reference Citation Analysis]
225 Mathew M, Tay E, Cusi K. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovasc Diabetol 2010;9:9. [PMID: 20158910 DOI: 10.1186/1475-2840-9-9] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 7.6] [Reference Citation Analysis]
226 Veelen A, Erazo-Tapia E, Oscarsson J, Schrauwen P. Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment? Mol Metab 2021;46:101158. [PMID: 33387681 DOI: 10.1016/j.molmet.2020.101158] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
227 Filipova E, Uzunova K, Kalinov K, Vekov T. Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis. Diabetol Metab Syndr. 2017;9:90. [PMID: 29163673 DOI: 10.1186/s13098-017-0290-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
228 Berardis S, Sattwika PD, Najimi M, Sokal EM. Use of mesenchymal stem cells to treat liver fibrosis: Current situation and future prospects. World J Gastroenterol 2015; 21(3): 742-758 [PMID: 25624709 DOI: 10.3748/wjg.v21.i3.742] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 71] [Article Influence: 10.6] [Reference Citation Analysis]
229 Hossain N, Kanwar P, Mohanty SR. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract 2016;2016:7109270. [PMID: 27006654 DOI: 10.1155/2016/7109270] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
230 Gawrieh S, Chalasani N. Pharmacotherapy for Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2015;35:338-48. [PMID: 26378648 DOI: 10.1055/s-0035-1562951] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
231 Razavizade M, Jamali R, Arj A, Matini SM, Moraveji A, Taherkhani E. The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial. Hepat Mon. 2013;13:e9270. [PMID: 23930133 DOI: 10.5812/hepatmon.9270] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
232 Kleiner DE, Makhlouf HR. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis 2016;20:293-312. [PMID: 27063270 DOI: 10.1016/j.cld.2015.10.011] [Cited by in Crossref: 111] [Cited by in F6Publishing: 90] [Article Influence: 15.9] [Reference Citation Analysis]
233 Mahjoubin-Tehran M, De Vincentis A, Mikhailidis DP, Atkin SL, Mantzoros CS, Jamialahmadi T, Sahebkar A. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Mol Metab 2021;50:101049. [PMID: 32673798 DOI: 10.1016/j.molmet.2020.101049] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
234 Petta S, Macaluso FS, Barcellona MR, Cammà C, Cabibi D, Di Marco V, Craxì A. Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. PLoS One. 2012;7:e51165. [PMID: 23227248 DOI: 10.1371/journal.pone.0051165] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
235 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3478/wjg.v20.i7.1712] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
236 Mukherjee S. Advances in the treatment of nonalcoholic steatohepatitis. World J Pharmacol 2020; 9(1): 1-12 [DOI: 10.5497/wjp.v9.i1.1] [Reference Citation Analysis]
237 Khashab MA, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep 2008;10:73-80. [DOI: 10.1007/s11894-008-0012-0] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 3.4] [Reference Citation Analysis]
238 Sutinen J. The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients. PPAR Res 2009;2009:373524. [PMID: 19096512 DOI: 10.1155/2009/373524] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
239 Xiao F, Waldrop SL, Bronk SF, Gores GJ, Davis LS, Kilic G. Lipoapoptosis induced by saturated free fatty acids stimulates monocyte migration: a novel role for Pannexin1 in liver cells. Purinergic Signal. 2015;11:347-359. [PMID: 26054298 DOI: 10.1007/s11302-015-9456-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
240 Patel NS, Doycheva I, Peterson MR, Hooker J, Kisselva T, Schnabl B, Seki E, Sirlin CB, Loomba R. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2015;13:561-568.e1. [PMID: 25218667 DOI: 10.1016/j.cgh.2014.08.039] [Cited by in Crossref: 81] [Cited by in F6Publishing: 82] [Article Influence: 10.1] [Reference Citation Analysis]
241 Desouza CV, Shivaswamy V. Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review. Clin Med Insights Endocrinol Diabetes 2010;3:43-51. [PMID: 22879786 DOI: 10.4137/cmed.s5372] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
242 Uhl P, Fricker G, Haberkorn U, Mier W. Current status in the therapy of liver diseases. Int J Mol Sci. 2014;15:7500-7512. [PMID: 24786290 DOI: 10.3390/ijms15057500] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
243 Matthews L, Kleiner DE, Chairez C, McManus M, Nettles MJ, Zemanick K, Morse CG, Benator D, Kovacs JA, Hadigan C. Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection. AIDS Res Hum Retroviruses. 2015;31:961-966. [PMID: 26214341 DOI: 10.1089/aid.2015.0093] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
244 Mulder P, Morrison MC, Verschuren L, Liang W, van Bockel JH, Kooistra T, Wielinga PY, Kleemann R. Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice. Sci Rep 2016;6:31542. [PMID: 27545964 DOI: 10.1038/srep31542] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
245 Lipska K, Inzucchi SE. Cardiovascular risk-benefit ratio of thiazolidinediones. Curr Cardio Risk Rep 2009;3:42-50. [DOI: 10.1007/s12170-009-0008-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
246 Yu HH, Hsieh MC, Wu SY, Sy ED, Shan YS. Effects of duodenal-jejunal bypass surgery in ameliorating nonalcoholic steatohepatitis in diet-induced obese rats. Diabetes Metab Syndr Obes 2019;12:149-59. [PMID: 30705600 DOI: 10.2147/DMSO.S190631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
247 Pala L, Barbaro V, Dicembrini I, Rotella CM. The therapy of insulin resistance in other diseases besides type 2 diabetes. Eat Weight Disord 2014;19:275-83. [PMID: 25069836 DOI: 10.1007/s40519-014-0139-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
248 Bettermann K, Hohensee T, Haybaeck J. Steatosis and steatohepatitis: complex disorders. Int J Mol Sci. 2014;15:9924-9944. [PMID: 24897026 DOI: 10.3390/ijms15069924] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
249 Bedossa P. Current histological classification of NAFLD: Strength and limitations. Hepatol Int. 2013;7 Suppl 2:765-770. [PMID: 26202292 DOI: 10.1007/s12072-013-9446-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
250 Grizales AM, Patti ME, Lin AP, Beckman JA, Sahni VA, Cloutier E, Fowler KM, Dreyfuss JM, Pan H, Kozuka C, Lee A, Basu R, Pober DM, Gerszten RE, Goldfine AB. Metabolic Effects of Betaine: A Randomized Clinical Trial of Betaine Supplementation in Prediabetes. J Clin Endocrinol Metab 2018;103:3038-49. [PMID: 29860335 DOI: 10.1210/jc.2018-00507] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
251 Yu Y, Cai J, She Z, Li H. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. Adv Sci (Weinh). 2019;6:1801585. [PMID: 30828530 DOI: 10.1002/advs.201801585] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
252 Tolman KG, Freston JW, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf. 2009;32:787-800. [PMID: 19670918 DOI: 10.2165/11316510-000000000-00000] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
253 Erstad DJ, Razavi AA, Li S, Tanabe KK, Fuchs BC. Prevention Strategies for Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 255-89. [DOI: 10.1007/978-3-030-21540-8_13] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
254 Paschou SA, Polyzos SA, Anagnostis P, Goulis DG, Kanaka-Gantenbein C, Lambrinoudaki I, Georgopoulos NA, Vryonidou A. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Endocrine 2020;67:1-8. [PMID: 31538291 DOI: 10.1007/s12020-019-02085-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
255 Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab 2021;50:101122. [PMID: 33220492 DOI: 10.1016/j.molmet.2020.101122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
256 Martins FO, Delgado TC, Viegas J, Gaspar JM, Scott DK, O'Doherty RM, Macedo MP, Jones JG. Mechanisms by which the thiazolidinedione troglitazone protects against sucrose-induced hepatic fat accumulation and hyperinsulinaemia. Br J Pharmacol 2016;173:267-78. [PMID: 26447327 DOI: 10.1111/bph.13362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
257 Iizuka Y, Kim H, Nakasatomi M, Izawa T, Hirako S, Matsumoto A. Fish oil prevents excessive accumulation of subcutaneous fat caused by an adverse effect of pioglitazone treatment and positively changes adipocytes in KK mice. Toxicol Rep 2016;3:4-14. [PMID: 28959521 DOI: 10.1016/j.toxrep.2015.11.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
258 Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One. 2011;6:e25269. [PMID: 21957486 DOI: 10.1371/journal.pone.0025269] [Cited by in Crossref: 151] [Cited by in F6Publishing: 155] [Article Influence: 13.7] [Reference Citation Analysis]
259 Kořínková L, Pražienková V, Černá L, Karnošová A, Železná B, Kuneš J, Maletínská L. Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides. Front Endocrinol (Lausanne) 2020;11:597583. [PMID: 33324348 DOI: 10.3389/fendo.2020.597583] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
260 Jalili R, Somi MH, Hosseinifard H, Salehnia F, Ghojazadeh M, Makhdami N, Shirmohammadi M. The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. Adv Pharm Bull. 2020;10:542-555. [PMID: 33072533 DOI: 10.34172/apb.2020.065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
261 Grattagliano I, Di Ciaula A, Baj J, Molina-Molina E, Shanmugam H, Garruti G, Wang DQ, Portincasa P. Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). Methods Mol Biol 2021;2310:201-46. [PMID: 34096005 DOI: 10.1007/978-1-0716-1433-4_12] [Reference Citation Analysis]
262 Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, Itoh Y, Yoshikawa T, Fukui M, Hasegawa G, Nakamura N, Ohta M, Obayashi H, Okanoue T. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011;46:101-7. [DOI: 10.1007/s00535-010-0291-8] [Cited by in Crossref: 126] [Cited by in F6Publishing: 117] [Article Influence: 10.5] [Reference Citation Analysis]
263 Lingvay I, Roe ED, Duong J, Leonard D, Szczepaniak LS. Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes. J Investig Med 2012;60:1059-63. [PMID: 22801247 DOI: 10.2310/JIM.0b013e3182621c5f] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
264 Cazanave SC, Elmi NA, Akazawa Y, Bronk SF, Mott JL, Gores GJ. CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. Am J Physiol Gastrointest Liver Physiol. 2010;299:G236-G243. [PMID: 20430872 DOI: 10.1152/ajpgi.00091.2010] [Cited by in Crossref: 126] [Cited by in F6Publishing: 127] [Article Influence: 10.5] [Reference Citation Analysis]
265 Snyder HS, Sakaan SA, March KL, Siddique O, Cholankeril R, Cummings CD, Gadiparthi C, Satapathy SK, Ahmed A, Cholankeril G. Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies. J Clin Transl Hepatol. 2018;6:168-174. [PMID: 29951362 DOI: 10.14218/jcth.2017.00050] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
266 Zhang C, Liao Y, Li Q, Chen M, Zhao Q, Deng R, Wu C, Yang A, Guo Z, Wang D. Recombinant adiponectin ameliorates liver ischemia reperfusion injury via activating the AMPK/eNOS pathway. PLoS One. 2013;8:e66382. [PMID: 23762489 DOI: 10.1371/journal.pone.0066382] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
267 Yoon HJ, Cha BS. Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease. World J Hepatol 2014; 6(11): 800-811 [PMID: 25429318 DOI: 10.4254/wjh.v6.i11.800] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
268 Hirata T, Tomita K, Kawai T, Yokoyama H, Shimada A, Kikuchi M, Hirose H, Ebinuma H, Irie J, Ojiro K. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). Int J Endocrinol. 2013;2013:587140. [PMID: 23997767 DOI: 10.1155/2013/587140] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 4.1] [Reference Citation Analysis]
269 Yoneda M, Honda Y, Ogawa Y, Kessoku T, Kobayashi T, Imajo K, Ozaki A, Nogami A, Taguri M, Yamanaka T, Kirikoshi H, Iwasaki T, Kurihashi T, Saito S, Nakajima A. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.BMJ Open Diabetes Res Care. 2021;9. [PMID: 33593749 DOI: 10.1136/bmjdrc-2020-001990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
270 Pisano G, Fracanzani AL, Caccamo L, Donato MF, Fargion S. Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study. World J Gastroenterol 2016; 22(40): 8869-8882 [PMID: 27833378 DOI: 10.3748/wjg.v22.i40.8869] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
271 McVicker BL, Bennett RG. Novel Anti-fibrotic Therapies. Front Pharmacol 2017;8:318. [PMID: 28620300 DOI: 10.3389/fphar.2017.00318] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
272 Boutari C, Perakakis N, Mantzoros CS. Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul). 2018;33:33-43. [PMID: 29589386 DOI: 10.3803/enm.2018.33.1.33] [Cited by in Crossref: 61] [Cited by in F6Publishing: 36] [Article Influence: 15.3] [Reference Citation Analysis]
273 van der Poorten D, George J. Current and novel therapies for the treatment of nonalcoholic steatohepatitis. Hepatol Int 2007;1:343-54. [PMID: 19669329 DOI: 10.1007/s12072-007-9011-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
274 Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells 2020;9:E1638. [PMID: 32650421 DOI: 10.3390/cells9071638] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
275 Khullar V, Dolganiuc A, Firpi RJ. Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease. World J Transplant 2014; 4(2): 81-92 [PMID: 25032097 DOI: 10.5500/wjt.v4.i2.81] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
276 Sprenger S, Woldemariam T, Kotchoni S, Elshabrawy HA, Chaturvedi LS. Lemongrass essential oil and its major constituent citral isomers modulate adipogenic gene expression in 3T3-L1 cells. J Food Biochem 2022;:e14037. [PMID: 34981531 DOI: 10.1111/jfbc.14037] [Reference Citation Analysis]
277 Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A, Prokisch H, Trümbach D, Mao G, Qu F, Bayir H, Füllekrug J, Scheel CH, Wurst W, Schick JA, Kagan VE, Angeli JP, Conrad M. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 2017;13:91-8. [PMID: 27842070 DOI: 10.1038/nchembio.2239] [Cited by in Crossref: 613] [Cited by in F6Publishing: 614] [Article Influence: 102.2] [Reference Citation Analysis]
278 Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. Gut. 2007;56:1760-1769. [PMID: 17911352 DOI: 10.1136/gut.2006.112094] [Cited by in Crossref: 161] [Cited by in F6Publishing: 148] [Article Influence: 10.7] [Reference Citation Analysis]
279 Tseng HT, Park YJ, Lee YK, Moore DD. The orphan nuclear receptor small heterodimer partner is required for thiazolidinedione effects in leptin-deficient mice. J Biomed Sci 2015;22:30. [PMID: 25951943 DOI: 10.1186/s12929-015-0133-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
280 Ono M, Okamoto N, Saibara T. The latest idea in NAFLD/NASH pathogenesis. Clin J Gastroenterol. 2010;3:263-270. [PMID: 26190482 DOI: 10.1007/s12328-010-0182-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
281 Lee JI, Lee HW, Lee KS. Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis. World J Gastroenterol 2019; 25(33): 4959-4969 [PMID: 31543686 DOI: 10.3748/wjg.v25.i33.4959] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
282 Mendez-Sanchez N, Cruz-Ramon VC, Ramirez-Perez OL, Hwang JP, Barranco-Fragoso B, Cordova-Gallardo J. New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis. Int J Mol Sci. 2018;19. [PMID: 30011790 DOI: 10.3390/ijms19072034] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 15.3] [Reference Citation Analysis]
283 Tsai LW, Lu YH, Dubey R, Chiou JF. Reenvisioning Traditional to Regenerative Therapeutic Advances in Managing Nonalcoholic Fatty Liver Disease in Diabetes Mellitus. J Diabetes Res 2021;2021:7692447. [PMID: 34805412 DOI: 10.1155/2021/7692447] [Reference Citation Analysis]
284 Lian J, Fu J. Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes: A Network Meta-Analysis. Front Endocrinol (Lausanne) 2021;12:649018. [PMID: 33841337 DOI: 10.3389/fendo.2021.649018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
285 Pratt DS. Liver disorders. Curr Opin Gastroenterol 2008;24:265-8. [PMID: 18408453 DOI: 10.1097/MOG.0b013e3282fbd371] [Reference Citation Analysis]
286 Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G, Franchini M, Zoppini G, Muggeo M. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19:1564-1570. [PMID: 18385424 DOI: 10.1681/asn.2007101155] [Cited by in Crossref: 122] [Cited by in F6Publishing: 51] [Article Influence: 8.7] [Reference Citation Analysis]
287 Lin M, Zhao S, Shen L, Xu D. Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition. Drug Saf 2014;37:213-24. [PMID: 24627311 DOI: 10.1007/s40264-014-0147-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
288 Rafie R, Hosseini SA, Hajiani E, Saki Malehi A, Mard SA. Effect of Ginger Powder Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Clin Exp Gastroenterol 2020;13:35-45. [PMID: 32158249 DOI: 10.2147/CEG.S234698] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
289 Shiba K, Tsuchiya K, Komiya C, Miyachi Y, Mori K, Shimazu N, Yamaguchi S, Ogasawara N, Katoh M, Itoh M, Suganami T, Ogawa Y. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci Rep. 2018;8:2362. [PMID: 29402900 DOI: 10.1038/s41598-018-19658-7] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 14.8] [Reference Citation Analysis]
290 Portillo-Sanchez P, Cusi K. Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. Clin Diabetes Endocrinol 2016;2:9. [PMID: 28702244 DOI: 10.1186/s40842-016-0027-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
291 Filozof C, Goldstein BJ, Williams RN, Sanyal A. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs 2015;75:1373-92. [PMID: 26201461 DOI: 10.1007/s40265-015-0437-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
292 Sumida Y, Yoneda M, Toyoda H, Yasuda S, Tada T, Hayashi H, Nishigaki Y, Suzuki Y, Naiki T, Morishita A, Tobita H, Sato S, Kawabe N, Fukunishi S, Ikegami T, Kessoku T, Ogawa Y, Honda Y, Nakahara T, Munekage K, Ochi T, Sawada K, Takahashi A, Arai T, Kogiso T, Kimoto S, Tomita K, Notsumata K, Nonaka M, Kawata K, Takami T, Kumada T, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone? Int J Mol Sci 2020;21:E4939. [PMID: 32668632 DOI: 10.3390/ijms21144939] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
293 Pydyn N, Miękus K, Jura J, Kotlinowski J. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis. Pharmacol Rep 2020;72:1-12. [PMID: 32016853 DOI: 10.1007/s43440-019-00020-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
294 Rana H, Yadav SS, Reddy HD, Singhal S, Singh DK, Usman K. Comparative Effect of Insulin Sensitizers and Statin on Metabolic Profile and Ultrasonographical Score in Non Alcoholic Fatty Liver Disease. J Clin Diagn Res 2016;10:OC19-23. [PMID: 27656480 DOI: 10.7860/JCDR/2016/19887.8336] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
295 Sharma BC, Kumar A, Garg V, Reddy RS, Sakhuja P, Sarin SK. A Randomized Controlled Trial Comparing Efficacy of Pentoxifylline and Pioglitazone on Metabolic Factors and Liver Histology in Patients with Non-alcoholic Steatohepatitis. J Clin Exp Hepatol. 2012;2:333-337. [PMID: 25755455 DOI: 10.1016/j.jceh.2012.10.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
296 Cazanave SC, Mott JL, Elmi NA, Bronk SF, Masuoka HC, Charlton MR, Gores GJ. A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA. J Lipid Res. 2011;52:1517-1525. [PMID: 21633093 DOI: 10.1194/jlr.m014654] [Cited by in Crossref: 58] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
297 Yan HM, Xia MF, Wang Y, Chang XX, Yao XZ, Rao SX, Zeng MS, Tu YF, Feng R, Jia WP, Liu J, Deng W, Jiang JD, Gao X. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PLoS One. 2015;10:e0134172. [PMID: 26252777 DOI: 10.1371/journal.pone.0134172] [Cited by in Crossref: 88] [Cited by in F6Publishing: 86] [Article Influence: 12.6] [Reference Citation Analysis]
298 Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2012;35:66-75. [PMID: 22050199 DOI: 10.1111/j.1365-2036.2011.04912.x] [Cited by in Crossref: 186] [Cited by in F6Publishing: 167] [Article Influence: 16.9] [Reference Citation Analysis]
299 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutr Metab Cardiovasc Dis 2022;32:1-16. [PMID: 34924246 DOI: 10.1016/j.numecd.2021.04.028] [Reference Citation Analysis]
300 Fielding CM, Angulo P. Hepatic steatosis and steatohepatitis: Are they really two distinct entities? Curr Hepatol Rep 2014;13:151-8. [PMID: 24977111 DOI: 10.1007/s11901-014-0227-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
301 Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest. 2013;123:1887-1901. [PMID: 23635787 DOI: 10.1172/jci66028] [Cited by in Crossref: 393] [Cited by in F6Publishing: 226] [Article Influence: 43.7] [Reference Citation Analysis]
302 Weiß J, Rau M, Geier A. Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int 2014;111:447-52. [PMID: 25019921 DOI: 10.3238/arztebl.2014.0447] [Cited by in Crossref: 19] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
303 Kang S, Moon MK, Kim W, Koo BK. Association between muscle strength and advanced fibrosis in non-alcoholic fatty liver disease: a Korean nationwide survey. J Cachexia Sarcopenia Muscle 2020;11:1232-41. [PMID: 32638541 DOI: 10.1002/jcsm.12598] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
304 Cobo Martín M, Fernández Gil P, Crespo J. [Treatment of fatty liver disease]. Gastroenterol Hepatol 2008;31:229-38. [PMID: 18405489 DOI: 10.1157/13117902] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
305 Dixon AE, Subramanian M, DeSarno M, Black K, Lane L, Holguin F. A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity. Respir Res 2015;16:143. [PMID: 26610598 DOI: 10.1186/s12931-015-0303-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
306 Merat S, Aduli M, Kazemi R, Sotoudeh M, Sedighi N, Sohrabi M, Malekzadeh R. Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. Dig Dis Sci. 2008;53:2246-2250. [PMID: 18049900 DOI: 10.1007/s10620-007-0109-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
307 Thiagarajan P, Aithal GP. Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges. J Clin Exp Hepatol 2019;9:515-21. [PMID: 31516268 DOI: 10.1016/j.jceh.2019.03.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
308 Marks KM, Kitch D, Chung RT, Hadigan C, Andersen J, Tien P, Luetkemeyer A, Alston-Smith B, Glesby MJ; A5239 Team. Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239. J Acquir Immune Defic Syndr 2014;65:345-9. [PMID: 24525470 DOI: 10.1097/QAI.0000000000000073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
309 Satiya J, Snyder HS, Singh SP, Satapathy SK. Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis. Transl Gastroenterol Hepatol 2021;6:60. [PMID: 34805582 DOI: 10.21037/tgh-20-247] [Reference Citation Analysis]
310 Yanai H, Adachi H. The Low-Dose (7.5 mg/day) Pioglitazone Therapy. J Clin Med Res 2017;9:821-5. [PMID: 28912917 DOI: 10.14740/jocmr3144w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
311 Arab JP, Candia R, Zapata R, Muñoz C, Arancibia JP, Poniachik J, Soza A, Fuster F, Brahm J, Sanhueza E, Contreras J, Cuellar MC, Arrese M, Riquelme A. Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review. World J Gastroenterol 2014; 20(34): 12182-12201 [PMID: 25232252 DOI: 10.3748/wjg.v20.i34.12182] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
312 Yang H, Suh DH, Kim DH, Jung ES, Liu KH, Lee CH, Park CY. Metabolomic and lipidomic analysis of the effect of pioglitazone on hepatic steatosis in a rat model of obese Type 2 diabetes. Br J Pharmacol 2018;175:3610-25. [PMID: 29968381 DOI: 10.1111/bph.14434] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
313 Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21(13): 3777-3785 [PMID: 25852263 DOI: 10.3748/wjg.v21.i13.3777] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 68] [Article Influence: 9.9] [Reference Citation Analysis]
314 Watanabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol. 2008;43:509-518. [PMID: 18648737 DOI: 10.1007/s00535-008-2193-6] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 8.5] [Reference Citation Analysis]
315 Loomba R, Wesley R, Pucino F, Liang TJ, Kleiner DE, Lavine JE. Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials. Clin Gastroenterol Hepatol 2008;6:1243-8. [PMID: 18829391 DOI: 10.1016/j.cgh.2008.07.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
316 Peng Z, Borea PA, Varani K, Wilder T, Yee H, Chiriboga L, Blackburn MR, Azzena G, Resta G, Cronstein BN. Adenosine signaling contributes to ethanol-induced fatty liver in mice. J Clin Invest. 2009;119:582-594. [PMID: 19221436 DOI: 10.1172/jci37409] [Cited by in Crossref: 120] [Cited by in F6Publishing: 63] [Article Influence: 9.2] [Reference Citation Analysis]
317 Tsochatzis EA, Papatheodoridis GV. Is there any progress in the treatment of non-alcoholic fatty liver disease? World J Gastrointest Pharmacol Ther 2011; 2(1): 1-5 [PMID: 21577310 DOI: 10.4292/wjgpt.v2.i1.1] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
318 Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, Richards L, Salotti J, Bhatt A, Hooker J, Haufe W, Hooker C, Brenner DA, Sirlin CB, Loomba R. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. J Hepatol. 2016;65:369-376. [PMID: 27151177 DOI: 10.1016/j.jhep.2016.04.021] [Cited by in Crossref: 186] [Cited by in F6Publishing: 169] [Article Influence: 31.0] [Reference Citation Analysis]
319 Jiang C, Wang Y, Jin Q, Zhang D, Gao M, Yao N, Yin Z, Zhang J, Ma S. Cyclocarya paliurus Triterpenoids Improve Diabetes-Induced Hepatic Inflammation via the Rho-Kinase-Dependent Pathway. Front Pharmacol 2019;10:811. [PMID: 31404259 DOI: 10.3389/fphar.2019.00811] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
320 Katsuyama H, Fukunaga T, Hamasaki H, Adachi H, Moriyama S, Kawaguchi A, Mishima S, Sako A, Yanai H. The Influences of Withdrawal and Daily Dose Reduction of Pioglitazone on Metabolic Parameters in Patients With Type 2 Diabetes: A Retrospective Longitudinal Observational Study. J Clin Med Res 2016;8:585-90. [PMID: 27429679 DOI: 10.14740/jocmr2611w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
321 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(7): 1712-1723 [PMID: 24587650 DOI: 10.3748/wjg.v20.i7.1712] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 73] [Article Influence: 9.8] [Reference Citation Analysis]
322 Qi J, Fong Y, Saltz L, D'Angelica MI, Kemeny NE, Gonen M, Shia J, Shukla-Dave A, Jarnagin WR, Do RK, Schwartz LH, Koutcher JA, Zakian KL. Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1 H MRS study. NMR Biomed 2013;26:204-12. [PMID: 22961714 DOI: 10.1002/nbm.2837] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
323 Ando W, Yokomori H, Tsutsui N, Yamanouchi E, Suzuki Y, Oda M, Inagaki Y, Otori K, Okazaki I. Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis. Clin Mol Hepatol. 2018;24:61-76. [PMID: 29151327 DOI: 10.3350/cmh.2017.0030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
324 Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE. Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol. 2008;153:636-645. [PMID: 17906687 DOI: 10.1038/sj.bjp.0707452] [Cited by in Crossref: 89] [Cited by in F6Publishing: 81] [Article Influence: 5.9] [Reference Citation Analysis]
325 Lettner A, Roden M. Ectopic fat and insulin resistance. Curr Diab Rep 2008;8:185-91. [PMID: 18625114 DOI: 10.1007/s11892-008-0032-z] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
326 Dongiovanni P, Rametta R, Fracanzani AL, Benedan L, Borroni V, Maggioni P, Maggioni M, Fargion S, Valenti L. Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterol. 2010;10:102. [PMID: 20825652 DOI: 10.1186/1471-230x-10-102] [Cited by in Crossref: 42] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
327 Beaton MD. Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can J Gastroenterol. 2012;26:353-357. [PMID: 22720278 DOI: 10.1155/2012/725468] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
328 David D, Eapen CE. What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease? J Clin Exp Hepatol 2021;11:232-8. [PMID: 33746449 DOI: 10.1016/j.jceh.2020.09.001] [Reference Citation Analysis]
329 Yau H, Rivera K, Lomonaco R, Cusi K. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep. 2013;13:329-341. [PMID: 23625197 DOI: 10.1007/s11892-013-0378-8] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 7.5] [Reference Citation Analysis]
330 Ganguli S, DeLeeuw P, Satapathy SK. A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis. Hepat Med 2019;11:159-78. [PMID: 31814783 DOI: 10.2147/HMER.S188991] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
331 Zhang F, Kong D, Lu Y, Zheng S. Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside. Cell Mol Life Sci 2013;70:259-76. [DOI: 10.1007/s00018-012-1046-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 5.1] [Reference Citation Analysis]
332 Carnevale Schianca GP, Sola D, Rossi L, Fra GP, Bartoli E. The management of type 2 diabetic patients with hypoglycemic agents. ISRN Endocrinol 2012;2012:601380. [PMID: 22577575 DOI: 10.5402/2012/601380] [Reference Citation Analysis]
333 Akazawa Y, Guicciardi ME, Cazanave SC, Bronk SF, Werneburg NW, Kakisaka K, Nakao K, Gores GJ. Degradation of cIAPs contributes to hepatocyte lipoapoptosis. Am J Physiol Gastrointest Liver Physiol. 2013;305:G611-G619. [PMID: 24008361 DOI: 10.1152/ajpgi.00111.2013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
334 Ghadieh HE, Muturi HT, Russo L, Marino CC, Ghanem SS, Khuder SS, Hanna JC, Jash S, Puri V, Heinrich G, Gatto-Weis C, Lee KY, Najjar SM. Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis. Hepatol Commun 2018;2:35-47. [PMID: 29404511 DOI: 10.1002/hep4.1117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
335 Vatner DF, Goedeke L, Camporez JG, Lyu K, Nasiri AR, Zhang D, Bhanot S, Murray SF, Still CD, Gerhard GS, Shulman GI, Samuel VT. Angptl8 antisense oligonucleotide improves adipose lipid metabolism and prevents diet-induced NAFLD and hepatic insulin resistance in rodents. Diabetologia 2018;61:1435-46. [PMID: 29497783 DOI: 10.1007/s00125-018-4579-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
336 Xiao F, Waldrop SL, Khimji AK, Kilic G. Pannexin1 contributes to pathophysiological ATP release in lipoapoptosis induced by saturated free fatty acids in liver cells. Am J Physiol Cell Physiol 2012;303:C1034-44. [PMID: 22972801 DOI: 10.1152/ajpcell.00175.2012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
337 Dongiovanni P, Valenti L. Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility? PPAR Res. 2013;2013:452061. [PMID: 23431284 DOI: 10.1155/2013/452061] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
338 Richard J, Lingvay I. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther. 2011;9:321-328. [PMID: 21438811 DOI: 10.1586/erc.11.15] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
339 Yokoo T, Bydder M, Hamilton G, Middleton MS, Gamst AC, Wolfson T, Hassanein T, Patton HM, Lavine JE, Schwimmer JB, Sirlin CB. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology. 2009;251:67-76. [PMID: 19221054 DOI: 10.1148/radiol.2511080666] [Cited by in Crossref: 239] [Cited by in F6Publishing: 228] [Article Influence: 18.4] [Reference Citation Analysis]
340 Rosell M, Jones MC, Parker MG. Role of nuclear receptor corepressor RIP140 in metabolic syndrome. Biochim Biophys Acta 2011;1812:919-28. [PMID: 21193034 DOI: 10.1016/j.bbadis.2010.12.016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
341 Gupta AK, Bray GA, Greenway FL, Martin CK, Johnson WD, Smith SR. Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes. J Diabetes Complications 2010;24:289-96. [PMID: 19577936 DOI: 10.1016/j.jdiacomp.2009.05.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
342 Xiao Y, Kim M, Lazar MA. Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease. Mol Metab 2021;50:101119. [PMID: 33220489 DOI: 10.1016/j.molmet.2020.101119] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
343 Shao JL, Hu GX. Blood glucose, blood glucose fluctuation and hepatic fibrosis. Shijie Huaren Xiaohua Zazhi 2010; 18(13): 1301-1305 [DOI: 10.11569/wcjd.v18.i13.1301] [Reference Citation Analysis]
344 Skat-Rørdam J, Højland Ipsen D, Lykkesfeldt J, Tveden-Nyborg P. A role of peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease. Basic Clin Pharmacol Toxicol 2019;124:528-37. [PMID: 30561132 DOI: 10.1111/bcpt.13190] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 11.7] [Reference Citation Analysis]
345 Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia. 2008;51:1781-1789. [PMID: 18726585 DOI: 10.1007/s00125-008-1116-7] [Cited by in Crossref: 158] [Cited by in F6Publishing: 133] [Article Influence: 11.3] [Reference Citation Analysis]
346 Zollner G, Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br J Pharmacol 2009;156:7-27. [PMID: 19133988 DOI: 10.1111/j.1476-5381.2008.00030.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 81] [Article Influence: 6.6] [Reference Citation Analysis]
347 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol 2014; 20(36): 12956-12980 [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956] [Cited by in CrossRef: 109] [Cited by in F6Publishing: 91] [Article Influence: 13.6] [Reference Citation Analysis]
348 Syn WK, Teaberry V, Choi SS, Diehl AM. Similarities and differences in the pathogenesis of alcoholic and nonalcoholic steatohepatitis. Semin Liver Dis 2009;29:200-10. [PMID: 19387919 DOI: 10.1055/s-0029-1214375] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
349 DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36 Suppl 2:S127-S138. [PMID: 23882037 DOI: 10.2337/dcs13-2011] [Cited by in Crossref: 145] [Cited by in F6Publishing: 72] [Article Influence: 18.1] [Reference Citation Analysis]
350 Satapathy SK, Nair S, Vanatta JM. Nonalcoholic fatty liver disease following liver transplantation. Hepatol Int 2013;7:400-12. [PMID: 26201774 DOI: 10.1007/s12072-013-9434-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
351 Dyson JK, Anstee QM, McPherson S. Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. Postgrad Med J 2015;91:92-101. [PMID: 25655252 DOI: 10.1136/postgradmedj-2013-100404rep] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
352 Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol. 2010;21:406-412. [PMID: 20150538 DOI: 10.1681/asn.2009080820] [Cited by in Crossref: 210] [Cited by in F6Publishing: 101] [Article Influence: 17.5] [Reference Citation Analysis]
353 Xia MF, Yan HM, He WY, Li XM, Li CL, Yao XZ, Li RK, Zeng MS, Gao X. Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method. Obesity (Silver Spring). 2012;20:444-452. [PMID: 22016092 DOI: 10.1038/oby.2011.302] [Cited by in Crossref: 78] [Cited by in F6Publishing: 78] [Article Influence: 7.1] [Reference Citation Analysis]
354 Jornayvaz FR, Lee HY, Jurczak MJ, Alves TC, Guebre-Egziabher F, Guigni BA, Zhang D, Samuel VT, Silva JE, Shulman GI. Thyroid hormone receptor-α gene knockout mice are protected from diet-induced hepatic insulin resistance. Endocrinology. 2012;153:583-591. [PMID: 22147010 DOI: 10.1210/en.2011-1793] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 4.2] [Reference Citation Analysis]
355 Van Gaal LF, Mertens J, Francque S, De Block C. Therapeutic approaches for non-alcoholic steatohepatitis. Ther Adv Endocrinol Metab 2021;12:20420188211034300. [PMID: 34497708 DOI: 10.1177/20420188211034300] [Reference Citation Analysis]
356 Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95. [PMID: 19336687 DOI: 10.2337/db09-9028] [Cited by in Crossref: 1576] [Cited by in F6Publishing: 1391] [Article Influence: 121.2] [Reference Citation Analysis]
357 Yoo JJ, Kim W, Kim MY, Jun DW, Kim SG, Yeon JE, Lee JW, Cho YK, Park SH, Sohn JH; the Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG). Recent research trends and updates on nonalcoholic fatty liver disease. Clin Mol Hepatol 2019;25:1-11. [PMID: 30086613 DOI: 10.3350/cmh.2018.0037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
358 Kita Y, Takamura T, Misu H, Ota T, Kurita S, Takeshita Y, Uno M, Matsuzawa-Nagata N, Kato K, Ando H. Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. PLoS One. 2012;7:e43056. [PMID: 23028442 DOI: 10.1371/journal.pone.0043056] [Cited by in Crossref: 84] [Cited by in F6Publishing: 82] [Article Influence: 8.4] [Reference Citation Analysis]
359 Menéndez Torre E, Lafita Tejedor FJ, Artola Menéndez S, Millán Núñez-Cortés J, Alonso García A, Puig Domingo M, García Solans JR, Alvarez Guisasola F, García Alegría J, Mediavilla Bravo J, Miranda Fernández-Santos C, Romero González R; Grupo de Trabajo de Consensos y Guías Clínicas de la Sociedad Española de Diabetes. [Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes]. Aten Primaria 2011;43:202.e1-9. [PMID: 21382648 DOI: 10.1016/j.aprim.2010.07.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
360 Bedossa P. Histological Assessment of NAFLD. Dig Dis Sci. 2016;61:1348-1355. [PMID: 26874689 DOI: 10.1007/S10620-016-4052-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
361 Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol. 2011;4:249-263. [PMID: 21765869 DOI: 10.1177/1756283x11403809] [Cited by in Crossref: 49] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
362 Joy TR, McKenzie CA, Tirona RG, Summers K, Seney S, Chakrabarti S, Malhotra N, Beaton MD. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J Gastroenterol 2017; 23(1): 141-150 [PMID: 28104990 DOI: 10.3748/wjg.v23.i1.141] [Cited by in CrossRef: 80] [Cited by in F6Publishing: 70] [Article Influence: 16.0] [Reference Citation Analysis]
363 Gharaibeh NE, Rahhal MN, Rahimi L, Ismail-Beigi F. SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions. Diabetes Metab Syndr Obes 2019;12:1001-12. [PMID: 31308716 DOI: 10.2147/DMSO.S212715] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
364 Stål P. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World J Gastroenterol 2015; 21(39): 11077-11087 [PMID: 26494963 DOI: 10.3748/wjg.v21.i39.11077] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 66] [Article Influence: 10.0] [Reference Citation Analysis]
365 Temple JL, Cordero P, Li J, Nguyen V, Oben JA. A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. Int J Mol Sci 2016;17:E947. [PMID: 27314342 DOI: 10.3390/ijms17060947] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 12.8] [Reference Citation Analysis]
366 Kim KS, Lee BW, Kim YJ, Lee DH, Cha BS, Park CY. Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment. Diabetes Metab J 2019;43:127-43. [PMID: 30993937 DOI: 10.4093/dmj.2019.0034] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
367 Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol. 2014;5:277-286. [PMID: 25285192 DOI: 10.1136/flgastro-2013-100404] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 7.5] [Reference Citation Analysis]
368 Majumdar A, Verbeek J, Tsochatzis EA. Non-alcoholic fatty liver disease: Current therapeutic options. Curr Opin Pharmacol 2021;61:98-105. [PMID: 34688168 DOI: 10.1016/j.coph.2021.09.007] [Reference Citation Analysis]
369 Mallat A, Lotersztajn S. [Liver fibrosis: from pathophysiology to therapeutic openings]. Gastroenterol Clin Biol 2009;33:789-98. [PMID: 19560889 DOI: 10.1016/j.gcb.2009.05.004] [Reference Citation Analysis]
370 Léveillé M, Estall JL. Mitochondrial Dysfunction in the Transition from NASH to HCC. Metabolites 2019;9:E233. [PMID: 31623280 DOI: 10.3390/metabo9100233] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
371 Heydari M, Cornide-Petronio ME, Jiménez-Castro MB, Peralta C. Data on Adiponectin from 2010 to 2020: Therapeutic Target and Prognostic Factor for Liver Diseases? Int J Mol Sci 2020;21:E5242. [PMID: 32718097 DOI: 10.3390/ijms21155242] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
372 Corey KE, Rinella ME. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. Dig Dis Sci 2016;61:1387-97. [PMID: 26942734 DOI: 10.1007/s10620-016-4083-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
373 Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes.Diabetol Metab Syndr. 2020;12:60. [PMID: 32684985 DOI: 10.1186/s13098-020-00570-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 17.5] [Reference Citation Analysis]
374 Francque SM, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus JV, Zelber-Sagi S, Hallsworth K, Busetto L, Frühbeck G, Dicker D, Woodward E, Korenjak M, Willemse J, Koek GH, Vinker S, Ungan M, Mendive JM, Lionis C. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep 2021;3:100322. [PMID: 34693236 DOI: 10.1016/j.jhepr.2021.100322] [Reference Citation Analysis]
375 Svegliati-Baroni G, Patrício B, Lioci G, Macedo MP, Gastaldelli A. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. Int J Mol Sci 2020;21:E5820. [PMID: 32823659 DOI: 10.3390/ijms21165820] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
376 Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, Malek M, Reza Babaei M, Zamani F, Ajdarkosh H, Khoonsari M, Fallah AE, Khamseh ME. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Diabetes Ther. 2021;12:843-861. [PMID: 33586120 DOI: 10.1007/s13300-021-01011-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
377 Kamolvisit S, Chirnaksorn S, Nimitphong H, Sungkanuparph S. Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes. Cureus 2021;13:e19046. [PMID: 34858740 DOI: 10.7759/cureus.19046] [Reference Citation Analysis]
378 Greuter T, Malhi H, Gores GJ, Shah VH. Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. JCI Insight 2017;2:95354. [PMID: 28878132 DOI: 10.1172/jci.insight.95354] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
379 Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, McCullough A. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54:344-353. [PMID: 21520200 DOI: 10.1002/hep.24376] [Cited by in Crossref: 431] [Cited by in F6Publishing: 407] [Article Influence: 39.2] [Reference Citation Analysis]
380 Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. Therap Adv Gastroenterol. 2009;2:157-163. [PMID: 21180541 DOI: 10.1177/1756283x09105462] [Cited by in Crossref: 86] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
381 Sattar N, Fitchett D, Hantel S, George JT, Zinman B. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. Diabetologia 2018;61:2155-63. [PMID: 30066148 DOI: 10.1007/s00125-018-4702-3] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 17.0] [Reference Citation Analysis]
382 Zarrinpar A, Loomba R. Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;36:909-921. [PMID: 23057494 DOI: 10.1111/apt.12084] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 6.7] [Reference Citation Analysis]
383 Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904. [DOI: 10.1007/s00125-011-2446-4] [Cited by in Crossref: 366] [Cited by in F6Publishing: 343] [Article Influence: 36.6] [Reference Citation Analysis]
384 Tacelli M, Celsa C, Magro B, Giannetti A, Pennisi G, Spatola F, Petta S. Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? Pharmaceuticals (Basel). 2018;11:121. [PMID: 30413050 DOI: 10.3390/ph11040121] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
385 Eldor R, DeFronzo RA, Abdul-Ghani M. In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care 2013;36 Suppl 2:S162-74. [PMID: 23882042 DOI: 10.2337/dcS13-2003] [Cited by in Crossref: 63] [Cited by in F6Publishing: 35] [Article Influence: 7.9] [Reference Citation Analysis]
386 Bian Z, Ma X. Liver fibrogenesis in non-alcoholic steatohepatitis. Front Physiol 2012;3:248. [PMID: 22934006 DOI: 10.3389/fphys.2012.00248] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
387 Hardy T, Anstee QM, Day CP. Nonalcoholic fatty liver disease: new treatments. Curr Opin Gastroenterol. 2015;31:175-183. [PMID: 25774446 DOI: 10.1097/mog.0000000000000175] [Cited by in Crossref: 61] [Cited by in F6Publishing: 32] [Article Influence: 10.2] [Reference Citation Analysis]
388 Bloomgarden ZT. World Congress on the Insulin Resistance Syndrome, 2009: the kidney, the liver, and insulin resistance. Diabetes Care 2010;33:e116-20. [PMID: 20805262 DOI: 10.2337/dc10-zb09] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
389 Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol. 2011;7:456-465. [PMID: 21556019 DOI: 10.1038/nrendo.2011.72] [Cited by in Crossref: 200] [Cited by in F6Publishing: 190] [Article Influence: 18.2] [Reference Citation Analysis]
390 Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int. 2017;37 Suppl 1:97-103. [PMID: 28052626 DOI: 10.1111/liv.13302] [Cited by in Crossref: 107] [Cited by in F6Publishing: 102] [Article Influence: 21.4] [Reference Citation Analysis]
391 Baran B, Akyüz F. Non-alcoholic fatty liver disease: What has changed in the treatment since the beginning? World J Gastroenterol 2014; 20(39): 14219-14229 [PMID: 25339808 DOI: 10.3748/wjg.v20.i39.14219] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
392 Majumdar SK, Inzucchi SE. Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? Endocrine 2013;44:47-58. [PMID: 23354728 DOI: 10.1007/s12020-013-9884-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
393 Zisser A, Ipsen DH, Tveden-Nyborg P. Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis-Roles as Putative Treatment Targets? Biomedicines 2021;9:365. [PMID: 33807461 DOI: 10.3390/biomedicines9040365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
394 Hartl L, Elias J, Prager G, Reiberger T, Unger LW. Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. World J Gastroenterol 2021; 27(19): 2281-2298 [PMID: 34040322 DOI: 10.3748/wjg.v27.i19.2281] [Reference Citation Analysis]
395 Itou M, Kawaguchi T, Taniguchi E, Oriishi T, Sata M. Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report. Case Rep Gastroenterol. 2012;6:538-544. [PMID: 22949894 DOI: 10.1159/000341510] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
396 Carr RM, Oranu A, Khungar V. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. Gastroenterol Clin North Am 2016;45:639-52. [PMID: 27837778 DOI: 10.1016/j.gtc.2016.07.003] [Cited by in Crossref: 89] [Cited by in F6Publishing: 77] [Article Influence: 14.8] [Reference Citation Analysis]
397 Ratziu V. Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol 2013;10:676-85. [PMID: 24126564 DOI: 10.1038/nrgastro.2013.193] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
398 Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008;118:829-38. [PMID: 18317565 DOI: 10.1172/JCI34275] [Cited by in Crossref: 779] [Cited by in F6Publishing: 413] [Article Influence: 55.6] [Reference Citation Analysis]
399 Regev A, Palmer M, Avigan MI, Dimick-Santos L, Treem WR, Marcinak JF, Seekins D, Krishna G, Anania FA, Freston JW, Lewis JH, Sanyal AJ, Chalasani N. Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2019;49:702-13. [PMID: 30761572 DOI: 10.1111/apt.15153] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
400 Tang A, Chen J, Le TA, Changchien C, Hamilton G, Middleton MS, Loomba R, Sirlin CB. Cross-sectional and longitudinal evaluation of liver volume and total liver fat burden in adults with nonalcoholic steatohepatitis. Abdom Imaging 2015;40:26-37. [PMID: 25015398 DOI: 10.1007/s00261-014-0175-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
401 Enooku K, Kondo M, Fujiwara N, Sasako T, Shibahara J, Kado A, Okushin K, Fujinaga H, Tsutsumi T, Nakagomi R, Minami T, Sato M, Nakagawa H, Kondo Y, Asaoka Y, Tateishi R, Ueki K, Ikeda H, Yoshida H, Moriya K, Yotsuyanagi H, Kadowaki T, Fukayama M, Koike K. Hepatic IRS1 and ß-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients. J Gastroenterol 2018;53:1261-75. [PMID: 29749571 DOI: 10.1007/s00535-018-1472-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
402 Koeckerling D, Tomlinson JW, Cobbold JF. Fighting liver fat. Endocr Connect 2020;9:R173-86. [PMID: 32621584 DOI: 10.1530/EC-20-0174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
403 Miyauchi S, Miyake T, Miyazaki M, Eguchi T, Niiya T, Yamamoto S, Senba H, Furukawa S, Matsuura B, Hiasa Y. Insulin-like growth factor-1 is inversely associated with liver fibrotic markers in patients with type 2 diabetes mellitus. J Diabetes Investig 2019;10:1083-91. [PMID: 30592792 DOI: 10.1111/jdi.13000] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
404 Gao L, Wang X, Lin Z, Song N, Liu X, Chi X, Shao T. Antidiabetic and Neuroprotective Effect of the N-Butanol Extract of Fragaria nilgerrensis Schlecht. in STZ-Induced Diabetic Mice. Evid Based Complement Alternat Med 2018;2018:6938370. [PMID: 30254687 DOI: 10.1155/2018/6938370] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
405 Choudhary NS, Kumar N, Duseja A. Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease. J Clin Exp Hepatol 2019;9:731-9. [PMID: 31889755 DOI: 10.1016/j.jceh.2019.06.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
406 Kawaguchi-Suzuki M, Bril F, Kalavalapalli S, Cusi K, Frye RF. Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2017;46:56-61. [PMID: 28470881 DOI: 10.1111/apt.14111] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
407 Berlanga A, Guiu-Jurado E, Porras JA, Aragonès G, Auguet T. [Role of metabolic lipases and lipotoxicity in the development of non-alcoholic steatosis and non-alcoholic steatohepatitis]. Clin Investig Arterioscler 2016;28:47-61. [PMID: 26049666 DOI: 10.1016/j.arteri.2015.03.003] [Reference Citation Analysis]
408 Mehal WZ, Schuppan D. Antifibrotic therapies in the liver. Semin Liver Dis. 2015;35:184-198. [PMID: 25974903 DOI: 10.1055/s-0035-1550055] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
409 Huiying Z, Guangying C, Shiyang Z. Design, synthesis and biological activity evaluation of a new class of 2,4-thiazolidinedione compounds as insulin enhancers. J Enzyme Inhib Med Chem 2019;34:981-9. [PMID: 31072232 DOI: 10.1080/14756366.2019.1608197] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
410 Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des. 2013;19:5219-5238. [PMID: 23394097 DOI: 10.2174/13816128113199990381] [Cited by in Crossref: 128] [Cited by in F6Publishing: 113] [Article Influence: 16.0] [Reference Citation Analysis]
411 Wang YX. PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Res 2010;20:124-37. [PMID: 20101262 DOI: 10.1038/cr.2010.13] [Cited by in Crossref: 183] [Cited by in F6Publishing: 179] [Article Influence: 15.3] [Reference Citation Analysis]
412 Leite NC, Villela-Nogueira CA, Cardoso CRL, Salles GF. Non-alcoholic fatty liver disease and diabetes: From physiopathological interplay to diagnosis and treatment. World J Gastroenterol 2014; 20(26): 8377-8392 [PMID: 25024596 DOI: 10.3748/wjg.v20.i26.8377] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
413 Kakisaka K, Cazanave SC, Fingas CD, Guicciardi ME, Bronk SF, Werneburg NW, Mott JL, Gores GJ. Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. Am J Physiol Gastrointest Liver Physiol. 2012;302:G77-G84. [PMID: 21995961 DOI: 10.1152/ajpgi.00301.2011] [Cited by in Crossref: 114] [Cited by in F6Publishing: 111] [Article Influence: 10.4] [Reference Citation Analysis]
414 Martins E, Oliveira A. NAFLD and cardiovascular disease. Porto Biomed J 2018;3:e2. [PMID: 31595238 DOI: 10.1016/j.pbj.0000000000000002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
415 Lomonaco R, Bril F, Portillo-Sanchez P, Ortiz-Lopez C, Orsak B, Biernacki D, Lo M, Suman A, Weber MH, Cusi K. Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes. Diabetes Care. 2016;39:632-638. [PMID: 26861926 DOI: 10.2337/dc15-1876] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 10.2] [Reference Citation Analysis]
416 Mehta SR. Advances in the treatment of nonalcoholic fatty liver disease. Ther Adv Endocrinol Metab. 2010;1:101-115. [PMID: 23148155 DOI: 10.1177/2042018810379587] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
417 Birech Z, Mwangi PW, Bukachi F, Mandela KM. Application of Raman spectroscopy in type 2 diabetes screening in blood using leucine and isoleucine amino-acids as biomarkers and in comparative anti-diabetic drugs efficacy studies. PLoS One 2017;12:e0185130. [PMID: 28926628 DOI: 10.1371/journal.pone.0185130] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
418 Pacana T, Sanyal AJ. Recent advances in understanding/management of non-alcoholic steatohepatitis. F1000Prime Rep. 2015;7:28. [PMID: 25926979 DOI: 10.12703/p7-28] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
419 Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism 2016;65:1096-108. [PMID: 26856933 DOI: 10.1016/j.metabol.2016.01.001] [Cited by in Crossref: 205] [Cited by in F6Publishing: 195] [Article Influence: 34.2] [Reference Citation Analysis]
420 Juluri R, Vuppalanchi R, Olson J, Unalp A, Van Natta ML, Cummings OW, Tonascia J, Chalasani N. Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol. 2011;45:55-58. [PMID: 20505526 DOI: 10.1097/mcg.0b013e3181dd1348] [Cited by in Crossref: 73] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
421 Tanwar S, Rhodes F, Srivastava A, Trembling PM, Rosenberg WM. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. World J Gastroenterol 2020; 26(2): 109-133 [PMID: 31969775 DOI: 10.3748/wjg.v26.i2.109] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
422 Vonghia L, Francque S. Cross talk of the immune system in the adipose tissue and the liver in non-alcoholic steatohepatitis: Pathology and beyond. World J Hepatol 2015; 7(15): 1905-1912 [PMID: 26244065 DOI: 10.4254/wjh.v7.i15.1905] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
423 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO). Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Eat Weight Disord 2021. [PMID: 34914079 DOI: 10.1007/s40519-021-01287-1] [Reference Citation Analysis]
424 Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, Kim YS, Lee JW, Kim DJ, Cho SW, Hwang SG, Sohn JH, Kim MY, Kim YB, Kim JG, Cho YK, Choi MS, Kim HJ, Lee HW, Kim SU, Kim JK, Choi JY, Jun DW, Tak WY, Lee BS, Jang BK, Chung WJ, Kim HS, Jang JY, Jeong SW, Kim SG, Kwon OS, Jung YK, Choe WH, Lee JS, Kim IH, Shim JJ, Cheon GJ, Bae SH, Seo YS, Choi DH, Jang SJ; Korean Association for the Study of the Liver. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18:1-21. [PMID: 22511898 DOI: 10.3350/kjhep.2012.18.1.1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 9.4] [Reference Citation Analysis]
425 Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, Unalp A, Tonascia J. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials. 2009;30:88-96. [PMID: 18804555 DOI: 10.1016/j.cct.2008.09.003] [Cited by in Crossref: 105] [Cited by in F6Publishing: 97] [Article Influence: 7.5] [Reference Citation Analysis]
426 Huard K, Brown J, Jones JC, Cabral S, Futatsugi K, Gorgoglione M, Lanba A, Vera NB, Zhu Y, Yan Q, Zhou Y, Vernochet C, Riccardi K, Wolford A, Pirman D, Niosi M, Aspnes G, Herr M, Genung NE, Magee TV, Uccello DP, Loria P, Di L, Gosset JR, Hepworth D, Rolph T, Pfefferkorn JA, Erion DM. Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5). Sci Rep 2015;5:17391. [PMID: 26620127 DOI: 10.1038/srep17391] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
427 Hui E, Xu A, Bo Yang H, Lam KS. Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines. J Diabetes Investig 2013;4:413-25. [PMID: 24843689 DOI: 10.1111/jdi.12093] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 5.2] [Reference Citation Analysis]
428 Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, Francque S, Farrell G, Kowdley KV, Craxi A, Simon K, Fischer L, Melchor-Khan L, Vest J, Wiens BL, Vig P, Seyedkazemi S, Goodman Z, Wong VW, Loomba R, Tacke F, Sanyal A, Lefebvre E. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018;67:1754-1767. [PMID: 28833331 DOI: 10.1002/hep.29477] [Cited by in Crossref: 314] [Cited by in F6Publishing: 309] [Article Influence: 78.5] [Reference Citation Analysis]
429 Lee CH, Lam KS. Managing non-alcoholic fatty liver disease in diabetes: Challenges and opportunities. J Diabetes Investig 2017;8:131-3. [PMID: 27181498 DOI: 10.1111/jdi.12534] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
430 Perdomo CM, Garcia-Fernandez N, Escalada J. Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate? J Clin Med 2021;10:2040. [PMID: 34068699 DOI: 10.3390/jcm10092040] [Reference Citation Analysis]
431 Ogawa Y, Yoneda M, Tomeno W, Imajo K, Shinohara Y, Fujita K, Shibata W, Kirikoshi H, Saito S, Wada K, Maeda S, Nakajima A. Peroxisome Proliferator-Activated Receptor Gamma Exacerbates Concanavalin A-Induced Liver Injury via Suppressing the Translocation of NF-κB into the Nucleus. PPAR Res 2012;2012:940384. [PMID: 23251143 DOI: 10.1155/2012/940384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
432 Bae JS, Lee DH, Lee JY, Kim H, Yu SJ, Lee JH, Cho EJ, Lee YB, Han JK, Choi BI. Assessment of hepatic steatosis by using attenuation imaging: a quantitative, easy-to-perform ultrasound technique. Eur Radiol. 2019;. [PMID: 31175413 DOI: 10.1007/s00330-019-06272-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
433 Davison BA, Edwards C, Loomba R, Harrison SA, Cotter G, Alkhouri N, Koch GG, Dittrich HC. Noninvasive measure of treatment response in non-alcoholic steatohepatitis: Insights from EMMINENCE and meta-analysis. JGH Open 2021;5:740-9. [PMID: 34263067 DOI: 10.1002/jgh3.12575] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
434 d'Assignies G, Fontés G, Kauffmann C, Latour M, Gaboury L, Boulanger Y, Van Beers BE, Soulez G, Poitout V, Tang A. Early detection of liver steatosis by magnetic resonance imaging in rats infused with glucose and intralipid solutions and correlation to insulin levels. Metabolism 2013;62:1850-7. [PMID: 24035445 DOI: 10.1016/j.metabol.2013.08.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
435 Mangi MA, Minhas AM, Rehman H, Pathan F, Liang H, Beidas S. Association of Non-alcoholic Fatty Liver Disease with Conduction Defects on Electrocardiogram. Cureus 2017;9:e1107. [PMID: 28439482 DOI: 10.7759/cureus.1107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
436 Patel Chavez C, Cusi K, Kadiyala S. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. J Clin Endocrinol Metab 2021:dgab578. [PMID: 34406410 DOI: 10.1210/clinem/dgab578] [Reference Citation Analysis]
437 Syn WK, Bruckner-Holt C, Farmer A, Howdle S, Bateman J. Liver biopsy in a district general hospital: Changes over two decades. World J Gastroenterol 2007; 13(40): 5336-5342 [PMID: 17879403 DOI: 10.3748/wjg.v13.i40.5336] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
438 Bobulescu IA, Dubree M, Zhang J, McLeroy P, Moe OW. Reduction of renal triglyceride accumulation: effects on proximal tubule Na+/H+ exchange and urinary acidification. Am J Physiol Renal Physiol 2009;297:F1419-26. [PMID: 19692486 DOI: 10.1152/ajprenal.00177.2009] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
439 Liu Q, Bengmark S, Qu S. The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis. 2010;9:42. [PMID: 20426802 DOI: 10.1186/1476-511x-9-42] [Cited by in Crossref: 108] [Cited by in F6Publishing: 54] [Article Influence: 9.0] [Reference Citation Analysis]
440 Hoffmann L, Seibt A, Herebian D, Spiekerkoetter U. Monounsaturated 14:1n-9 and 16:1n-9 fatty acids but not 18:1n-9 induce apoptosis and necrosis in murine HL-1 cardiomyocytes. Lipids 2014;49:25-37. [PMID: 24281896 DOI: 10.1007/s11745-013-3865-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
441 Heda R, Yazawa M, Shi M, Bhaskaran M, Aloor FZ, Thuluvath PJ, Satapathy SK. Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World J Gastroenterol 2021; 27(17): 1864-1882 [PMID: 34007127 DOI: 10.3748/wjg.v27.i17.1864] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
442 Dennis BB, Sallam S, Perumpail BJ, Shah ND, Kim D, Cholankeril G, Ahmed A. Management of Cardiometabolic Complications in Patients With Nonalcoholic Fatty Liver Disease: A Review of the Literature With Recommendations. J Clin Gastroenterol 2021;55:747-56. [PMID: 34469404 DOI: 10.1097/MCG.0000000000001555] [Reference Citation Analysis]
443 Bedossa P. Histological Assessment of NAFLD. Dig Dis Sci. 2016;61:1348-1355. [PMID: 26874689 DOI: 10.1007/s10620-016-4062-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
444 Huan Y, Pan X, Peng J, Jia C, Sun S, Bai G, Wang X, Zhou T, Li R, Liu S, Li C, Liu Q, Liu Z, Shen Z. A novel specific peroxisome proliferator-activated receptor γ (PPARγ) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese mice. Diabetes Obes Metab 2019;21:2553-63. [PMID: 31364797 DOI: 10.1111/dom.13843] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
445 Sawangjit R, Chongmelaxme B, Phisalprapa P, Saokaew S, Thakkinstian A, Kowdley KV, Chaiyakunapruk N. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore). 2016;95:e4529. [PMID: 27512874 DOI: 10.1097/md.0000000000004529] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 6.4] [Reference Citation Analysis]
446 Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, Hardies J, Cusi K. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 2012;35:873-8. [PMID: 22374640 DOI: 10.2337/dc11-1849] [Cited by in Crossref: 146] [Cited by in F6Publishing: 132] [Article Influence: 14.6] [Reference Citation Analysis]
447 Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab. 2010;95:829-836. [PMID: 20061429 DOI: 10.1210/jc.2009-1487] [Cited by in Crossref: 106] [Cited by in F6Publishing: 101] [Article Influence: 8.8] [Reference Citation Analysis]
448 Gandhi N, Lenton R, Bhartia M, Abbas A, Raju J, Ramachandran S. Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome. Springerplus. 2014;3:14. [PMID: 24455467 DOI: 10.1186/2193-1801-3-14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
449 Pais R, Moraru I, Ratziu V. Glitazones for human nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2011;4:325-34. [PMID: 21922031 DOI: 10.1177/1756283X11409793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
450 Yen FS, Yang YC, Hwu CM, Wei JC, Huang YH, Hou MC, Hsu CC. Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes. Liver Int. 2020;40:1089-1097. [PMID: 31960563 DOI: 10.1111/liv.14385] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
451 Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, Reusch JEB, Young-Hyman D, Das S, Kosiborod M; American Diabetes Association Professional Practice Committee., American Diabetes Association Professional Practice Committee:. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45:S46-59. [PMID: 34964869 DOI: 10.2337/dc22-S004] [Reference Citation Analysis]
452 Yano K, Seko Y, Takahashi A, Okishio S, Kataoka S, Takemura M, Okuda K, Mizuno N, Taketani H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan. Diagnostics (Basel) 2020;10:E86. [PMID: 32041289 DOI: 10.3390/diagnostics10020086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
453 Schreuder TC, Verwer BJ, Nieuwkerk CMV, Mulder CJ. Nonalcoholic fatty liver disease: An overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol 2008; 14(16): 2474-2486 [PMID: 18442193 DOI: 10.3748/wjg.14.2474] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 111] [Article Influence: 8.0] [Reference Citation Analysis]
454 Sakaue S, Kamigaki M, Yoshimura H, Nishimura M. Effects of replacing metformin with pioglitazone on glycemic control in japanese patients with poorly controlled type 2 diabetes mellitus: A 12-week, open-label, prospective study. Curr Ther Res Clin Exp 2008;69:364-77. [PMID: 24692813 DOI: 10.1016/j.curtheres.2008.08.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
455 Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res. 2012;2012:716404. [PMID: 22194737 DOI: 10.1155/2012/716404] [Cited by in Crossref: 98] [Cited by in F6Publishing: 100] [Article Influence: 8.9] [Reference Citation Analysis]
456 Patel SS, Siddiqui MS. Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. Drugs. 2019;79:75-84. [PMID: 30588564 DOI: 10.1007/s40265-018-1040-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
457 Patel NS, Doycheva I, Peterson MR, Hooker J, Kisselva T, Schnabl B, Seki E, Sirlin CB, Loomba R. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2015;13:561-568.e1. [PMID: 25218667 DOI: 10.1016/j.cgh.2014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
458 Ohki T, Isogawa A, Iwamoto M, Ohsugi M, Yoshida H, Toda N, Tagawa K, Omata M, Koike K. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ScientificWorldJournal. 2012;2012:496453. [PMID: 22927782 DOI: 10.1100/2012/496453] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 6.8] [Reference Citation Analysis]
459 Liss KH, Finck BN. PPARs and nonalcoholic fatty liver disease. Biochimie 2017;136:65-74. [PMID: 27916647 DOI: 10.1016/j.biochi.2016.11.009] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 17.2] [Reference Citation Analysis]
460 Jorge-Galarza E, Posadas-Romero C, Torres-Tamayo M, Medina-Urrutia AX, Rodas-Díaz MA, Posadas-Sánchez R, Vargas-Alarcón G, González-Salazar MD, Cardoso-Saldaña GC, Juárez-Rojas JG. Insulin Resistance in Adipose Tissue but Not in Liver Is Associated with Aortic Valve Calcification. Dis Markers 2016;2016:9085474. [PMID: 28127113 DOI: 10.1155/2016/9085474] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
461 He XX, Wu XL, Chen RP, Chen C, Liu XG, Wu BJ, Huang ZM. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016;11:e0162368. [PMID: 27711128 DOI: 10.1371/journal.pone.0162368] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 7.8] [Reference Citation Analysis]
462 Han S, Jiao J, Zhang W, Xu J, Wan Z, Zhang W, Gao X, Qin L. Dietary fiber prevents obesity-related liver lipotoxicity by modulating sterol-regulatory element binding protein pathway in C57BL/6J mice fed a high-fat/cholesterol diet. Sci Rep 2015;5:15256. [PMID: 26510459 DOI: 10.1038/srep15256] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 5.9] [Reference Citation Analysis]
463 Ozturk ZA, Kadayifci A. Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. World J Hepatol 2014; 6(4): 199-206 [PMID: 24799988 DOI: 10.4254/wjh.v6.i4.199] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
464 Lee YH, Kim JH, Kim SR, Jin HY, Rhee EJ, Cho YM, Lee BW. Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness. J Korean Med Sci 2017;32:60-9. [PMID: 27914133 DOI: 10.3346/jkms.2017.32.1.60] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 9.8] [Reference Citation Analysis]
465 Lin P, Lu JM, Wang YF, Gu W, Zhao RH, Yu J. Prevention Mechanism of 2,3,5,4'-Tetrahydroxy-stilbene-2-O-β-D-glucoside on Lipid Accumulation in Steatosis Hepatic L-02 Cell. Pharmacogn Mag 2017;13:245-53. [PMID: 28539716 DOI: 10.4103/0973-1296.204563] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
466 Cui J, Chen CH, Lo MT, Schork N, Bettencourt R, Gonzalez MP, Bhatt A, Hooker J, Shaffer K, Nelson KE, Long MT, Brenner DA, Sirlin CB, Loomba R, For The Genetics Of Nafld In Twins Consortium. Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study. Hepatology 2016;64:1547-58. [PMID: 27315352 DOI: 10.1002/hep.28674] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
467 Kallwitz ER, McLachlan A, Cotler SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2008; 14(1): 22-28 [PMID: 18176957 DOI: 10.3748/wjg.14.22] [Cited by in CrossRef: 101] [Cited by in F6Publishing: 99] [Article Influence: 7.2] [Reference Citation Analysis]
468 Aghamohammadzadeh N, Niafar M, Dalir Abdolahinia E, Najafipour F, Mohamadzadeh Gharebaghi S, Adabi K, Dalir Abdolahinia E, Ahadi H. The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients. Ther Adv Endocrinol Metab. 2015;6:56-60. [PMID: 25941563 DOI: 10.1177/2042018815574229] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
469 Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer. 2009;115:5651-5661. [PMID: 19834957 DOI: 10.1002/cncr.24687] [Cited by in Crossref: 257] [Cited by in F6Publishing: 239] [Article Influence: 21.4] [Reference Citation Analysis]
470 Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic Fatty Liver Disease: A Clinical Update. J Clin Transl Hepatol. 2017;5:384-393. [PMID: 29226105 DOI: 10.14218/jcth.2017.00013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 44] [Article Influence: 5.4] [Reference Citation Analysis]
471 Bloomgarden ZT. Approaches to treatment of type 2 diabetes. Diabetes Care 2008;31:1697-703. [PMID: 18663234 DOI: 10.2337/dc08-zb08] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
472 Kaji K, Yoshiji H, Ikenaka Y, Noguchi R, Aihara Y, Douhara A, Moriya K, Kawaratani H, Shirai Y, Yoshii J. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J Gastroenterol. 2014;49:481-491. [PMID: 23475323 DOI: 10.1007/s00535-013-0783-4] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 8.4] [Reference Citation Analysis]
473 Kim CW, Addy C, Kusunoki J, Anderson NN, Deja S, Fu X, Burgess SC, Li C, Ruddy M, Chakravarthy M, Previs S, Milstein S, Fitzgerald K, Kelley DE, Horton JD. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. Cell Metab 2017;26:394-406.e6. [PMID: 28768177 DOI: 10.1016/j.cmet.2017.07.009] [Cited by in Crossref: 106] [Cited by in F6Publishing: 107] [Article Influence: 26.5] [Reference Citation Analysis]